ONTOLOGY REPORT - ANNOTATIONS
| Term: | organooxygen compound |
|
| Accession: | CHEBI:36963
|
browse the term
|
| Definition: | An organochalcogen compound containing at least one carbon-oxygen bond. |
| Synonyms: | related_synonym: | organooxygen compounds |
| | xref: | CiteXplore:17586126 "PubMed citation" |
|
|
(1->4)-beta-D-glucan
|
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
1,2-didecanoylglycerol
|
| G |
Sprr1a |
small proline-rich protein 1A |
|
increases expression |
ISO |
2 |
185,463,951 |
185,465,849 |
RGD:6480464 |
CTD |
1,2-dilauroyl-sn-glycero-3-phosphocholine
|
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
EXP |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
increases activity |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
1-O-palmitoyl-2-O-arachidonoyl-sn-glycero-3-phosphocholine
|
| G |
Lipg |
lipase, endothelial |
|
increases hydrolysis |
ISO |
18 |
71,795,150 |
71,816,056 |
RGD:6480464 |
CTD |
2-arachidonoylglycerol
|
| G |
Abhd12 |
abhydrolase domain containing 12 |
|
increases hydrolysis |
ISO |
3 |
141,468,888 |
141,530,219 |
RGD:6480464 |
CTD |
| G |
Abhd6 |
abhydrolase domain containing 6 |
|
increases hydrolysis |
ISO |
15 |
18,846,512 |
18,894,003 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ces2h |
carboxylesterase 2H |
|
increases hydrolysis |
ISO |
19 |
34,910,981 |
34,925,547 |
RGD:6480464 |
CTD |
| G |
Ces2h |
carboxylesterase 2H |
|
multiple interactions |
ISO |
19 |
34,910,981 |
34,925,547 |
RGD:6480464 |
CTD |
| G |
Cnr1 |
cannabinoid receptor 1 (brain) |
|
increases expression |
EXP |
5 |
50,427,173 |
50,445,471 |
RGD:6480464 |
CTD |
| G |
Cnr1 |
cannabinoid receptor 1 (brain) |
|
increases expression |
EXP |
5 |
50,427,173 |
50,445,471 |
RGD:6480464 |
CTD |
| G |
Cnr1 |
cannabinoid receptor 1 (brain) |
|
multiple interactions |
EXP |
5 |
50,427,173 |
50,445,471 |
RGD:6480464 |
CTD |
| G |
Cnr1 |
cannabinoid receptor 1 (brain) |
|
multiple interactions |
EXP |
5 |
50,427,173 |
50,445,471 |
RGD:6480464 |
CTD |
| G |
Cnr1 |
cannabinoid receptor 1 (brain) |
|
multiple interactions |
ISO |
5 |
50,427,173 |
50,445,471 |
RGD:6480464 |
CTD |
| G |
Cnr1 |
cannabinoid receptor 1 (brain) |
|
increases expression |
EXP |
5 |
50,427,173 |
50,445,471 |
RGD:6480464 |
CTD |
| G |
Cnr2 |
cannabinoid receptor 2 (macrophage) |
|
multiple interactions |
ISO |
5 |
154,674,754 |
154,702,552 |
RGD:6480464 |
CTD |
| G |
Cnr2 |
cannabinoid receptor 2 (macrophage) |
|
multiple interactions |
ISO |
5 |
154,674,754 |
154,702,552 |
RGD:6480464 |
CTD |
| G |
Cnr2 |
cannabinoid receptor 2 (macrophage) |
|
affects response to substance |
ISO |
5 |
154,674,754 |
154,702,552 |
RGD:6480464 |
CTD |
| G |
Fmr1 |
fragile X mental retardation 1 |
|
multiple interactions |
ISO |
X |
154,756,031 |
154,793,782 |
RGD:6480464 |
CTD |
| G |
Fyn |
FYN oncogene related to SRC, FGR, YES |
|
multiple interactions |
EXP |
20 |
43,501,853 |
43,695,567 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
decreases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il2 |
interleukin 2 |
|
multiple interactions |
ISO |
2 |
123,655,005 |
123,659,709 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
decreases expression |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
|
multiple interactions |
EXP |
8 |
68,379,074 |
68,451,554 |
RGD:6480464 |
CTD |
| G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
|
multiple interactions |
EXP |
7 |
10,074,654 |
10,094,003 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mgll |
monoglyceride lipase |
|
increases hydrolysis |
ISO |
4 |
122,822,493 |
122,922,892 |
RGD:6480464 |
CTD |
| G |
Mgll |
monoglyceride lipase |
|
multiple interactions |
EXP |
4 |
122,822,493 |
122,922,892 |
RGD:6480464 |
CTD |
| G |
Mgll |
monoglyceride lipase |
|
increases hydrolysis |
EXP |
4 |
122,822,493 |
122,922,892 |
RGD:6480464 |
CTD |
| G |
Mgll |
monoglyceride lipase |
|
multiple interactions |
ISO |
4 |
122,822,493 |
122,922,892 |
RGD:6480464 |
CTD |
| G |
Potef |
POTE ankyrin domain family, member F |
|
increases expression |
EXP |
18 |
24,420,779 |
24,422,284 |
RGD:6480464 |
CTD |
| G |
Potef |
POTE ankyrin domain family, member F |
|
multiple interactions |
EXP |
18 |
24,420,779 |
24,422,284 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
affects binding |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
increases expression |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
|
multiple interactions |
EXP |
3 |
15,343,832 |
15,365,412 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases metabolic processing |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
|
multiple interactions |
EXP |
10 |
60,109,656 |
60,134,939 |
RGD:6480464 |
CTD |
alginic acid
|
| G |
Acan |
aggrecan |
|
increases expression |
ISO |
1 |
134,787,341 |
134,848,992 |
RGD:6480464 |
CTD |
| G |
Col10a1 |
collagen, type X, alpha 1 |
|
increases expression |
ISO |
20 |
38,725,164 |
38,731,513 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
multiple interactions |
ISO |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
arabinoxylan
|
| G |
Fgf7 |
fibroblast growth factor 7 |
|
increases expression |
ISO |
3 |
113,468,427 |
113,517,538 |
RGD:6480464 |
CTD |
carrageenan
|
| G |
Anxa1 |
annexin A1 |
|
affects response to substance |
ISO |
1 |
223,478,436 |
223,494,455 |
RGD:6480464 |
CTD |
| G |
Anxa1 |
annexin A1 |
|
multiple interactions |
ISO |
1 |
223,478,436 |
223,494,455 |
RGD:6480464 |
CTD |
| G |
Apcs |
amyloid P component, serum |
|
increases expression |
EXP |
13 |
89,112,845 |
89,113,641 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl3 |
chemokine (C-C motif) ligand 3 |
|
increases expression |
ISO |
10 |
71,744,559 |
71,746,109 |
RGD:6480464 |
CTD |
| G |
Ccl3 |
chemokine (C-C motif) ligand 3 |
|
multiple interactions |
ISO |
10 |
71,744,559 |
71,746,109 |
RGD:6480464 |
CTD |
| G |
Ccl3 |
chemokine (C-C motif) ligand 3 |
|
increases expression |
ISO |
10 |
71,744,559 |
71,746,109 |
RGD:6480464 |
CTD |
| G |
Ccl3 |
chemokine (C-C motif) ligand 3 |
|
increases expression |
ISO |
10 |
71,744,559 |
71,746,109 |
RGD:6480464 |
CTD |
| G |
Ccl5 |
chemokine (C-C motif) ligand 5 |
|
increases expression |
ISO |
10 |
71,605,791 |
71,610,330 |
RGD:6480464 |
CTD |
| G |
Ccl5 |
chemokine (C-C motif) ligand 5 |
|
multiple interactions |
EXP |
10 |
71,605,791 |
71,610,330 |
RGD:6480464 |
CTD |
| G |
Cxcl1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
increases expression |
ISO |
14 |
18,690,339 |
18,692,118 |
RGD:6480464 |
CTD |
| G |
Cxcl2 |
chemokine (C-X-C motif) ligand 2 |
|
increases expression |
ISO |
14 |
18,677,129 |
18,679,175 |
RGD:6480464 |
CTD |
| G |
Cxcl2 |
chemokine (C-X-C motif) ligand 2 |
|
multiple interactions |
EXP |
14 |
18,677,129 |
18,679,175 |
RGD:6480464 |
CTD |
| G |
Egr1 |
early growth response 1 |
|
increases expression |
ISO |
18 |
27,343,919 |
27,346,117 |
RGD:6480464 |
CTD |
| G |
Egr1 |
early growth response 1 |
|
multiple interactions |
ISO |
18 |
27,343,919 |
27,346,117 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Gal |
galanin/GMAP prepropeptide |
|
decreases response to substance |
ISO |
1 |
205,936,352 |
205,941,215 |
RGD:6480464 |
CTD |
| G |
Gpr132 |
G protein-coupled receptor 132 |
|
increases expression |
ISO |
6 |
137,851,214 |
137,856,343 |
RGD:6480464 |
CTD |
| G |
Gpr4 |
G protein-coupled receptor 4 |
|
increases expression |
ISO |
1 |
78,586,541 |
78,588,029 |
RGD:6480464 |
CTD |
| G |
Gpr65 |
G-protein coupled receptor 65 |
|
increases expression |
ISO |
6 |
122,432,615 |
122,433,628 |
RGD:6480464 |
CTD |
| G |
Hspa1a |
heat shock protein 1A |
|
increases expression |
EXP |
20 |
3,945,716 |
3,959,552 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
increases expression |
EXP |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
multiple interactions |
EXP |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
multiple interactions |
EXP |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
multiple interactions |
EXP |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
increases expression |
EXP |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
increases secretion |
EXP |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
multiple interactions |
EXP |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
increases expression |
EXP |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il1a |
interleukin 1 alpha |
|
multiple interactions |
ISO |
3 |
116,913,612 |
116,924,114 |
RGD:6480464 |
CTD |
| G |
Il1a |
interleukin 1 alpha |
|
decreases expression |
ISO |
3 |
116,913,612 |
116,924,114 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases secretion |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases secretion |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases secretion |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases secretion |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
multiple interactions |
EXP |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
increases activity |
EXP |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Mt1a |
metallothionein 1a |
|
multiple interactions |
ISO |
19 |
11,261,631 |
11,262,647 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Ngf |
nerve growth factor (beta polypeptide) |
|
increases expression |
EXP |
2 |
197,621,726 |
197,632,960 |
RGD:6480464 |
CTD |
| G |
Ngf |
nerve growth factor (beta polypeptide) |
|
multiple interactions |
EXP |
2 |
197,621,726 |
197,632,960 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
P2rx7 |
purinergic receptor P2X, ligand-gated ion channel, 7 |
|
multiple interactions |
EXP |
12 |
35,074,025 |
35,117,152 |
RGD:6480464 |
CTD |
| G |
Ptges |
prostaglandin E synthase |
|
increases expression |
EXP |
3 |
9,946,194 |
9,957,538 |
RGD:6480464 |
CTD |
| G |
Ptges2 |
prostaglandin E synthase 2 |
|
multiple interactions |
EXP |
3 |
11,521,214 |
11,528,395 |
RGD:6480464 |
CTD |
| G |
Ptges2 |
prostaglandin E synthase 2 |
|
increases activity |
EXP |
3 |
11,521,214 |
11,528,395 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
increases phosphorylation |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Selp |
selectin P |
|
increases expression |
EXP |
13 |
79,886,614 |
79,922,180 |
RGD:6480464 |
CTD |
| G |
Selp |
selectin P |
|
multiple interactions |
EXP |
13 |
79,886,614 |
79,922,180 |
RGD:6480464 |
CTD |
| G |
Sstr4 |
somatostatin receptor 4 |
|
decreases response to substance |
ISO |
3 |
137,150,419 |
137,152,284 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
increases secretion |
ISO |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tjp1 |
tight junction protein 1 |
|
multiple interactions |
ISO |
1 |
119,684,774 |
119,750,532 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases secretion |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases secretion |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases secretion |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases secretion |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
chitosan
|
| G |
Alad |
aminolevulinate dehydratase |
|
multiple interactions |
EXP |
5 |
79,505,645 |
79,515,983 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
multiple interactions |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Clec7a |
C-type lectin domain family 7, member A |
|
multiple interactions |
ISO |
4 |
166,723,515 |
166,734,681 |
RGD:6480464 |
CTD |
| G |
Clec7a |
C-type lectin domain family 7, member A |
|
decreases expression |
ISO |
4 |
166,723,515 |
166,734,681 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases activity |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
multiple interactions |
ISO |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
increases secretion |
ISO |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases secretion |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Mmp2 |
matrix metallopeptidase 2 |
|
multiple interactions |
EXP |
19 |
15,246,036 |
15,275,061 |
RGD:6480464 |
CTD |
| G |
Th |
tyrosine hydroxylase |
|
multiple interactions |
EXP |
1 |
203,164,253 |
203,171,506 |
RGD:6480464 |
CTD |
| G |
Tlr2 |
toll-like receptor 2 |
|
multiple interactions |
ISO |
2 |
175,607,990 |
175,613,992 |
RGD:6480464 |
CTD |
| G |
Tlr2 |
toll-like receptor 2 |
|
decreases expression |
ISO |
2 |
175,607,990 |
175,613,992 |
RGD:6480464 |
CTD |
| G |
Tlr4 |
toll-like receptor 4 |
|
decreases expression |
ISO |
5 |
83,564,100 |
83,577,735 |
RGD:6480464 |
CTD |
| G |
Tlr4 |
toll-like receptor 4 |
|
multiple interactions |
ISO |
5 |
83,564,100 |
83,577,735 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases secretion |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tph1 |
tryptophan hydroxylase 1 |
|
multiple interactions |
EXP |
1 |
97,186,071 |
97,207,551 |
RGD:6480464 |
CTD |
chondroitin sulfate
|
| G |
Bdkrb2 |
bradykinin receptor B2 |
|
multiple interactions |
EXP |
6 |
129,744,781 |
129,748,851 |
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
affects binding |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
C3 |
complement component 3 |
|
increases cleavage |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
C5 |
complement component 5 |
|
increases cleavage |
ISO |
3 |
14,011,115 |
14,102,744 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
affects binding |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
F12 |
coagulation factor XII (Hageman factor) |
|
increases activity |
ISO |
17 |
15,251,611 |
15,259,583 |
RGD:6480464 |
CTD |
| G |
Fgf10 |
fibroblast growth factor 10 |
|
affects binding |
ISO |
2 |
50,866,799 |
50,940,319 |
RGD:6480464 |
CTD |
| G |
Fgf10 |
fibroblast growth factor 10 |
|
affects binding |
ISO |
2 |
50,866,799 |
50,940,319 |
RGD:6480464 |
CTD |
| G |
Fgf16 |
fibroblast growth factor 16 |
|
affects binding |
EXP |
X |
93,870,484 |
93,880,067 |
RGD:6480464 |
CTD |
| G |
Fgf16 |
fibroblast growth factor 16 |
|
affects binding |
EXP |
X |
93,870,484 |
93,880,067 |
RGD:6480464 |
CTD |
| G |
Fgf18 |
fibroblast growth factor 18 |
|
affects binding |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Fgf18 |
fibroblast growth factor 18 |
|
affects binding |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
affects binding |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
affects binding |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf23 |
fibroblast growth factor 23 |
|
increases activity |
ISO |
4 |
163,468,604 |
163,476,325 |
RGD:6480464 |
CTD |
| G |
Gdnf |
glial cell derived neurotrophic factor |
|
affects binding |
ISO |
2 |
57,399,312 |
57,424,030 |
RGD:6480464 |
CTD |
| G |
Hbegf |
heparin-binding EGF-like growth factor |
|
affects binding |
ISO |
18 |
29,143,567 |
29,153,944 |
RGD:6480464 |
CTD |
| G |
Hbegf |
heparin-binding EGF-like growth factor |
|
affects binding |
ISO |
18 |
29,143,567 |
29,153,944 |
RGD:6480464 |
CTD |
| G |
Klkb1 |
kallikrein B, plasma 1 |
|
increases activity |
ISO |
16 |
50,248,935 |
50,272,279 |
RGD:6480464 |
CTD |
D-glucitol
|
| G |
Aqp9 |
aquaporin 9 |
|
multiple interactions |
ISO |
8 |
75,611,485 |
75,651,646 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
increases activity |
EXP |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
multiple interactions |
EXP |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases activity |
EXP |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Eif4e |
eukaryotic translation initiation factor 4E |
|
multiple interactions |
ISO |
2 |
236,072,748 |
236,104,714 |
RGD:6480464 |
CTD |
| G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
|
multiple interactions |
ISO |
16 |
69,110,522 |
69,123,895 |
RGD:6480464 |
CTD |
| G |
Ins1 |
insulin 1 |
|
multiple interactions |
EXP |
1 |
258,001,134 |
258,001,688 |
RGD:6480464 |
CTD |
| G |
Mapk10 |
mitogen activated protein kinase 10 |
|
multiple interactions |
ISO |
14 |
7,719,595 |
8,010,694 |
RGD:6480464 |
CTD |
| G |
Mapk10 |
mitogen activated protein kinase 10 |
|
increases activity |
ISO |
14 |
7,719,595 |
8,010,694 |
RGD:6480464 |
CTD |
| G |
Mapk12 |
mitogen-activated protein kinase 12 |
|
increases phosphorylation |
ISO |
7 |
127,430,881 |
127,441,274 |
RGD:6480464 |
CTD |
| G |
Mapk14 |
mitogen activated protein kinase 14 |
|
increases phosphorylation |
ISO |
20 |
6,939,249 |
7,000,378 |
RGD:6480464 |
CTD |
| G |
Mapk7 |
mitogen-activated protein kinase 7 |
|
increases activity |
ISO |
10 |
47,649,203 |
47,654,316 |
RGD:6480464 |
CTD |
| G |
Mapkapk2 |
mitogen-activated protein kinase-activated protein kinase 2 |
|
increases activity |
ISO |
13 |
43,994,943 |
44,041,504 |
RGD:6480464 |
CTD |
| G |
Mapkapk2 |
mitogen-activated protein kinase-activated protein kinase 2 |
|
multiple interactions |
ISO |
13 |
43,994,943 |
44,041,504 |
RGD:6480464 |
CTD |
| G |
Mapkapk2 |
mitogen-activated protein kinase-activated protein kinase 2 |
|
increases phosphorylation |
ISO |
13 |
43,994,943 |
44,041,504 |
RGD:6480464 |
CTD |
| G |
Mknk1 |
MAP kinase-interacting serine/threonine kinase 1 |
|
increases activity |
ISO |
5 |
136,100,236 |
136,141,344 |
RGD:6480464 |
CTD |
| G |
Oat |
ornithine aminotransferase |
|
multiple interactions |
EXP |
1 |
192,026,623 |
192,046,404 |
RGD:6480464 |
CTD |
| G |
Ubxn1 |
UBX domain protein 1 |
|
increases phosphorylation |
ISO |
1 |
211,541,002 |
211,544,682 |
RGD:6480464 |
CTD |
| G |
Ubxn1 |
UBX domain protein 1 |
|
increases phosphorylation |
ISO |
1 |
211,541,002 |
211,544,682 |
RGD:6480464 |
CTD |
D-mannitol
|
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
EXP |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Bad |
BCL2-associated agonist of cell death |
|
increases phosphorylation |
EXP |
1 |
209,617,373 |
209,626,292 |
RGD:6480464 |
CTD |
| G |
Bad |
BCL2-associated agonist of cell death |
|
multiple interactions |
EXP |
1 |
209,617,373 |
209,626,292 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
increases expression |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
increases expression |
ISO |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Igf1 |
insulin-like growth factor 1 |
|
multiple interactions |
ISO |
7 |
24,531,669 |
24,605,742 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
increases expression |
EXP |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
|
multiple interactions |
EXP |
8 |
68,379,074 |
68,451,554 |
RGD:6480464 |
CTD |
| G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
|
multiple interactions |
EXP |
7 |
10,074,654 |
10,094,003 |
RGD:6480464 |
CTD |
| G |
Myl9 |
myosin, light chain 9, regulatory |
|
decreases phosphorylation |
EXP |
3 |
147,190,252 |
147,193,865 |
RGD:6480464 |
CTD |
| G |
Nppa |
natriuretic peptide A |
|
increases expression |
ISO |
5 |
165,074,518 |
165,075,827 |
RGD:6480464 |
CTD |
| G |
Oat |
ornithine aminotransferase |
|
multiple interactions |
EXP |
1 |
192,026,623 |
192,046,404 |
RGD:6480464 |
CTD |
| G |
Pdcd4 |
programmed cell death 4 |
|
increases expression |
ISO |
1 |
260,183,648 |
260,202,032 |
RGD:6480464 |
CTD |
| G |
Pdcd4 |
programmed cell death 4 |
|
decreases expression |
ISO |
1 |
260,183,648 |
260,202,032 |
RGD:6480464 |
CTD |
| G |
Ptk2 |
protein tyrosine kinase 2 |
|
multiple interactions |
ISO |
7 |
110,933,298 |
111,084,554 |
RGD:6480464 |
CTD |
| G |
Slc12a1 |
solute carrier family 12 (sodium/potassium/chloride transporters), member 1 |
|
increases activity |
EXP |
3 |
112,455,897 |
112,534,752 |
RGD:6480464 |
CTD |
| G |
Slc12a1 |
solute carrier family 12 (sodium/potassium/chloride transporters), member 1 |
|
multiple interactions |
EXP |
3 |
112,455,897 |
112,534,752 |
RGD:6480464 |
CTD |
| G |
Src |
v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) |
|
multiple interactions |
EXP |
3 |
148,157,256 |
148,170,524 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tpd52 |
tumor protein D52 |
|
decreases expression |
ISO |
2 |
94,850,203 |
94,880,802 |
RGD:6480464 |
CTD |
| G |
Tpd52 |
tumor protein D52 |
|
increases expression |
ISO |
2 |
94,850,203 |
94,880,802 |
RGD:6480464 |
CTD |
D-ribitol
|
| G |
Taldo1 |
transaldolase 1 |
|
increases abundance |
ISO |
1 |
201,582,856 |
201,593,187 |
RGD:6480464 |
CTD |
dermatan sulfate
|
| G |
Bdnf |
brain-derived neurotrophic factor |
|
affects binding |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
multiple interactions |
ISO |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
Fgf10 |
fibroblast growth factor 10 |
|
affects binding |
ISO |
2 |
50,866,799 |
50,940,319 |
RGD:6480464 |
CTD |
| G |
Fgf16 |
fibroblast growth factor 16 |
|
affects binding |
EXP |
X |
93,870,484 |
93,880,067 |
RGD:6480464 |
CTD |
| G |
Fgf18 |
fibroblast growth factor 18 |
|
affects binding |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
affects binding |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
increases activity |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf23 |
fibroblast growth factor 23 |
|
increases activity |
ISO |
4 |
163,468,604 |
163,476,325 |
RGD:6480464 |
CTD |
| G |
Fgf7 |
fibroblast growth factor 7 |
|
increases activity |
ISO |
3 |
113,468,427 |
113,517,538 |
RGD:6480464 |
CTD |
| G |
Gdnf |
glial cell derived neurotrophic factor |
|
affects binding |
ISO |
2 |
57,399,312 |
57,424,030 |
RGD:6480464 |
CTD |
| G |
Hbegf |
heparin-binding EGF-like growth factor |
|
affects binding |
ISO |
18 |
29,143,567 |
29,153,944 |
RGD:6480464 |
CTD |
| G |
Mdk |
midkine |
|
affects binding |
ISO |
3 |
76,309,988 |
76,311,345 |
RGD:6480464 |
CTD |
| G |
Ptn |
pleiotrophin |
|
affects binding |
ISO |
4 |
64,078,755 |
64,160,135 |
RGD:6480464 |
CTD |
| G |
Serpind1 |
serpin peptidase inhibitor, clade D (heparin cofactor), member 1 |
|
multiple interactions |
ISO |
11 |
85,666,714 |
85,677,716 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
affects binding |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
dextran
|
| G |
Slc31a2 |
solute carrier family 31 (copper transporters), member 2 |
|
decreases uptake |
ISO |
5 |
79,281,958 |
79,292,436 |
RGD:6480464 |
CTD |
dextran sulfate
|
| G |
Apc |
adenomatous polyposis coli |
|
affects response to substance |
ISO |
18 |
26,732,147 |
26,790,383 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases cleavage |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Ccl11 |
chemokine (C-C motif) ligand 11 |
|
increases secretion |
ISO |
10 |
70,279,161 |
70,283,762 |
RGD:6480464 |
CTD |
| G |
Ccl11 |
chemokine (C-C motif) ligand 11 |
|
multiple interactions |
ISO |
10 |
70,279,161 |
70,283,762 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
increases secretion |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Cnr1 |
cannabinoid receptor 1 (brain) |
|
decreases response to substance |
ISO |
5 |
50,427,173 |
50,445,471 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
increases expression |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
increases expression |
ISO |
8 |
125,978,161 |
125,987,670 |
RGD:6480464 |
CTD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
multiple interactions |
ISO |
8 |
125,978,161 |
125,987,670 |
RGD:6480464 |
CTD |
| G |
Cxcl1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
multiple interactions |
ISO |
14 |
18,690,339 |
18,692,118 |
RGD:6480464 |
CTD |
| G |
Cxcl1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
increases expression |
ISO |
14 |
18,690,339 |
18,692,118 |
RGD:6480464 |
CTD |
| G |
Cxcl1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
increases expression |
ISO |
14 |
18,690,339 |
18,692,118 |
RGD:6480464 |
CTD |
| G |
Cxcl1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
increases secretion |
ISO |
14 |
18,690,339 |
18,692,118 |
RGD:6480464 |
CTD |
| G |
Cxcl1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
multiple interactions |
ISO |
14 |
18,690,339 |
18,692,118 |
RGD:6480464 |
CTD |
| G |
Cxcl2 |
chemokine (C-X-C motif) ligand 2 |
|
multiple interactions |
ISO |
14 |
18,677,129 |
18,679,175 |
RGD:6480464 |
CTD |
| G |
Cxcl2 |
chemokine (C-X-C motif) ligand 2 |
|
increases expression |
ISO |
14 |
18,677,129 |
18,679,175 |
RGD:6480464 |
CTD |
| G |
Cyba |
cytochrome b-245, alpha polypeptide |
|
increases expression |
ISO |
19 |
52,713,150 |
52,721,609 |
RGD:6480464 |
CTD |
| G |
Cybb |
cytochrome b-245, beta polypeptide |
|
increases expression |
ISO |
X |
25,514,572 |
25,547,181 |
RGD:6480464 |
CTD |
| G |
Edn2 |
endothelin 2 |
|
increases expression |
ISO |
5 |
140,742,686 |
140,747,580 |
RGD:6480464 |
CTD |
| G |
Ereg |
epiregulin |
|
decreases response to substance |
ISO |
14 |
18,521,069 |
18,534,844 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fosl1 |
fos-like antigen 1 |
|
increases expression |
ISO |
1 |
208,090,612 |
208,099,118 |
RGD:6480464 |
CTD |
| G |
Foxp3 |
forkhead box P3 |
|
multiple interactions |
ISO |
X |
26,950,006 |
26,965,329 |
RGD:6480464 |
CTD |
| G |
Foxp3 |
forkhead box P3 |
|
increases methylation |
ISO |
X |
26,950,006 |
26,965,329 |
RGD:6480464 |
CTD |
| G |
Gast |
gastrin |
|
decreases response to substance |
ISO |
10 |
89,273,628 |
89,276,192 |
RGD:6480464 |
CTD |
| G |
Grk6 |
G protein-coupled receptor kinase 6 |
|
multiple interactions |
ISO |
17 |
15,220,992 |
15,236,617 |
RGD:6480464 |
CTD |
| G |
Grk6 |
G protein-coupled receptor kinase 6 |
|
decreases response to substance |
ISO |
17 |
15,220,992 |
15,236,617 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
increases expression |
ISO |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
multiple interactions |
ISO |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
increases expression |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
increases expression |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
increases expression |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
increases secretion |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Igf1 |
insulin-like growth factor 1 |
|
multiple interactions |
ISO |
7 |
24,531,669 |
24,605,742 |
RGD:6480464 |
CTD |
| G |
Ikbkb |
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta |
|
multiple interactions |
ISO |
16 |
73,804,730 |
73,858,510 |
RGD:6480464 |
CTD |
| G |
Ikbkb |
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta |
|
increases activity |
ISO |
16 |
73,804,730 |
73,858,510 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
decreases expression |
ISO |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
multiple interactions |
ISO |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
increases expression |
ISO |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
multiple interactions |
ISO |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
decreases expression |
ISO |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il12a |
interleukin 12A |
|
affects response to substance |
ISO |
2 |
158,710,261 |
158,717,689 |
RGD:6480464 |
CTD |
| G |
Il15 |
interleukin 15 |
|
increases response to substance |
ISO |
19 |
27,487,268 |
27,498,973 |
RGD:6480464 |
CTD |
| G |
Il15 |
interleukin 15 |
|
decreases expression |
EXP |
19 |
27,487,268 |
27,498,973 |
RGD:6480464 |
CTD |
| G |
Il15 |
interleukin 15 |
|
multiple interactions |
EXP |
19 |
27,487,268 |
27,498,973 |
RGD:6480464 |
CTD |
| G |
Il18 |
interleukin 18 |
|
affects response to substance |
ISO |
8 |
53,936,584 |
53,943,228 |
RGD:6480464 |
CTD |
| G |
Il18r1 |
interleukin 18 receptor 1 |
|
affects response to substance |
ISO |
9 |
39,627,915 |
39,659,828 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il27ra |
interleukin 27 receptor, alpha |
|
decreases response to substance |
ISO |
19 |
25,795,355 |
25,807,317 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Itgal |
integrin, alpha L |
|
multiple interactions |
ISO |
1 |
186,561,795 |
186,598,908 |
RGD:6480464 |
CTD |
| G |
Itgal |
integrin, alpha L |
|
increases expression |
ISO |
1 |
186,561,795 |
186,598,908 |
RGD:6480464 |
CTD |
| G |
Lep |
leptin |
|
multiple interactions |
ISO |
4 |
55,943,837 |
55,945,938 |
RGD:6480464 |
CTD |
| G |
Lta |
lymphotoxin alpha (TNF superfamily, member 1) |
|
increases expression |
ISO |
20 |
3,657,842 |
3,659,848 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases activity |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases activity |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mcm3 |
minichromosome maintenance complex component 3 |
|
increases expression |
ISO |
9 |
19,536,922 |
19,554,871 |
RGD:6480464 |
CTD |
| G |
Mki67 |
antigen identified by monoclonal antibody Ki-67 |
|
multiple interactions |
EXP |
1 |
195,310,027 |
195,336,224 |
RGD:6480464 |
CTD |
| G |
Mmp10 |
matrix metallopeptidase 10 (stromelysin 2) |
|
increases expression |
ISO |
8 |
4,367,842 |
4,375,737 |
RGD:6480464 |
CTD |
| G |
Mmp13 |
matrix metallopeptidase 13 |
|
increases expression |
ISO |
8 |
4,158,887 |
4,169,166 |
RGD:6480464 |
CTD |
| G |
Mmp13 |
matrix metallopeptidase 13 |
|
multiple interactions |
ISO |
8 |
4,158,887 |
4,169,166 |
RGD:6480464 |
CTD |
| G |
Mmp13 |
matrix metallopeptidase 13 |
|
increases expression |
ISO |
8 |
4,158,887 |
4,169,166 |
RGD:6480464 |
CTD |
| G |
Mmp2 |
matrix metallopeptidase 2 |
|
increases expression |
ISO |
19 |
15,246,036 |
15,275,061 |
RGD:6480464 |
CTD |
| G |
Mmp2 |
matrix metallopeptidase 2 |
|
multiple interactions |
ISO |
19 |
15,246,036 |
15,275,061 |
RGD:6480464 |
CTD |
| G |
Mmp3 |
matrix metallopeptidase 3 |
|
increases expression |
ISO |
8 |
4,315,601 |
4,329,146 |
RGD:6480464 |
CTD |
| G |
Mmp3 |
matrix metallopeptidase 3 |
|
increases expression |
ISO |
8 |
4,315,601 |
4,329,146 |
RGD:6480464 |
CTD |
| G |
Mmp3 |
matrix metallopeptidase 3 |
|
multiple interactions |
ISO |
8 |
4,315,601 |
4,329,146 |
RGD:6480464 |
CTD |
| G |
Mmp3 |
matrix metallopeptidase 3 |
|
increases expression |
ISO |
8 |
4,315,601 |
4,329,146 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
increases expression |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
multiple interactions |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
multiple interactions |
ISO |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
multiple interactions |
EXP |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
increases activity |
EXP |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
multiple interactions |
EXP |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
multiple interactions |
ISO |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
increases activity |
ISO |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
increases activity |
EXP |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
increases expression |
EXP |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
multiple interactions |
EXP |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
multiple interactions |
EXP |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
increases activity |
EXP |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
increases activity |
EXP |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
increases activity |
EXP |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
increases activity |
ISO |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
increases expression |
ISO |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
|
affects response to substance |
ISO |
3 |
58,366,693 |
58,394,116 |
RGD:6480464 |
CTD |
| G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
|
decreases expression |
ISO |
3 |
58,366,693 |
58,394,116 |
RGD:6480464 |
CTD |
| G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
|
multiple interactions |
ISO |
3 |
58,366,693 |
58,394,116 |
RGD:6480464 |
CTD |
| G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
multiple interactions |
EXP |
2 |
233,091,013 |
233,187,501 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
increases expression |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
increases phosphorylation |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
affects response to substance |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Ocln |
occludin |
|
decreases expression |
ISO |
2 |
31,317,090 |
31,367,485 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
increases cleavage |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Pcna |
proliferating cell nuclear antigen |
|
multiple interactions |
ISO |
3 |
120,008,715 |
120,012,589 |
RGD:6480464 |
CTD |
| G |
Pcna |
proliferating cell nuclear antigen |
|
multiple interactions |
EXP |
3 |
120,008,715 |
120,012,589 |
RGD:6480464 |
CTD |
| G |
Pgf |
placental growth factor |
|
decreases expression |
EXP |
6 |
109,215,540 |
109,226,122 |
RGD:6480464 |
CTD |
| G |
Pgf |
placental growth factor |
|
multiple interactions |
EXP |
6 |
109,215,540 |
109,226,122 |
RGD:6480464 |
CTD |
| G |
Phex |
phosphate regulating endopeptidase homolog, X-linked |
|
increases expression |
ISO |
X |
58,911,144 |
59,168,857 |
RGD:6480464 |
CTD |
| G |
Pik3r5 |
phosphoinositide-3-kinase, regulatory subunit 5 |
|
increases expression |
ISO |
10 |
55,227,872 |
55,248,301 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
increases expression |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Ptges |
prostaglandin E synthase |
|
multiple interactions |
ISO |
3 |
9,946,194 |
9,957,538 |
RGD:6480464 |
CTD |
| G |
Ptges |
prostaglandin E synthase |
|
increases expression |
ISO |
3 |
9,946,194 |
9,957,538 |
RGD:6480464 |
CTD |
| G |
Ptges |
prostaglandin E synthase |
|
multiple interactions |
EXP |
3 |
9,946,194 |
9,957,538 |
RGD:6480464 |
CTD |
| G |
Ptges |
prostaglandin E synthase |
|
increases expression |
EXP |
3 |
9,946,194 |
9,957,538 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
increases activity |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rps6 |
ribosomal protein S6 |
|
multiple interactions |
ISO |
5 |
106,165,612 |
106,168,472 |
RGD:6480464 |
CTD |
| G |
Rps6 |
ribosomal protein S6 |
|
multiple interactions |
ISO |
5 |
106,165,612 |
106,168,472 |
RGD:6480464 |
CTD |
| G |
S100a8 |
S100 calcium binding protein A8 |
|
increases expression |
ISO |
2 |
182,961,994 |
182,962,513 |
RGD:6480464 |
CTD |
| G |
Serpina5 |
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 |
|
multiple interactions |
ISO |
6 |
128,156,901 |
128,161,334 |
RGD:6480464 |
CTD |
| G |
Sirt1 |
sirtuin 1 |
|
multiple interactions |
ISO |
20 |
25,675,302 |
25,686,494 |
RGD:6480464 |
CTD |
| G |
Sirt1 |
sirtuin 1 |
|
decreases expression |
ISO |
20 |
25,675,302 |
25,686,494 |
RGD:6480464 |
CTD |
| G |
Sirt1 |
sirtuin 1 |
|
decreases expression |
ISO |
20 |
25,675,302 |
25,686,494 |
RGD:6480464 |
CTD |
| G |
Sirt1 |
sirtuin 1 |
|
multiple interactions |
ISO |
20 |
25,675,302 |
25,686,494 |
RGD:6480464 |
CTD |
| G |
Slc2a1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
increases expression |
ISO |
5 |
139,690,801 |
139,719,021 |
RGD:6480464 |
CTD |
| G |
Stat3 |
signal transducer and activator of transcription 3 (acute-phase response factor) |
|
multiple interactions |
EXP |
10 |
89,821,078 |
89,872,970 |
RGD:6480464 |
CTD |
| G |
Stat3 |
signal transducer and activator of transcription 3 (acute-phase response factor) |
|
multiple interactions |
ISO |
10 |
89,821,078 |
89,872,970 |
RGD:6480464 |
CTD |
| G |
Tfrc |
transferrin receptor |
|
increases expression |
ISO |
11 |
69,976,258 |
69,998,098 |
RGD:6480464 |
CTD |
| G |
Tk1 |
thymidine kinase 1, soluble |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Tlr4 |
toll-like receptor 4 |
|
multiple interactions |
ISO |
5 |
83,564,100 |
83,577,735 |
RGD:6480464 |
CTD |
| G |
Tlr4 |
toll-like receptor 4 |
|
increases expression |
ISO |
5 |
83,564,100 |
83,577,735 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases secretion |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnfrsf1b |
tumor necrosis factor receptor superfamily, member 1b |
|
increases expression |
ISO |
5 |
163,666,541 |
163,697,484 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases expression |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
|
affects expression |
ISO |
10 |
60,109,656 |
60,134,939 |
RGD:6480464 |
CTD |
| G |
Tst |
thiosulfate sulfurtransferase |
|
multiple interactions |
ISO |
7 |
116,349,579 |
116,355,921 |
RGD:6480464 |
CTD |
| G |
Tst |
thiosulfate sulfurtransferase |
|
decreases expression |
ISO |
7 |
116,349,579 |
116,355,921 |
RGD:6480464 |
CTD |
| G |
Tyms |
thymidylate synthetase |
|
multiple interactions |
ISO |
9 |
112,604,912 |
112,617,706 |
RGD:6480464 |
CTD |
| G |
Vcam1 |
vascular cell adhesion molecule 1 |
|
multiple interactions |
ISO |
2 |
212,277,654 |
212,297,376 |
RGD:6480464 |
CTD |
| G |
Vcam1 |
vascular cell adhesion molecule 1 |
|
increases expression |
ISO |
2 |
212,277,654 |
212,297,376 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
increases expression |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
dioleoyl phosphatidylcholine
|
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
EXP |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Lcat |
lecithin cholesterol acyltransferase |
|
affects binding |
ISO |
19 |
35,781,507 |
35,784,966 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
multiple interactions |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
dipalmitoyl phosphatidylglycerol
|
| G |
Pon1 |
paraoxonase 1 |
|
multiple interactions |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
glycerol
|
| G |
Ada |
adenosine deaminase |
|
multiple interactions |
ISO |
3 |
154,636,530 |
154,660,637 |
RGD:6480464 |
CTD |
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
increases abundance |
EXP |
19 |
54,738,556 |
54,750,349 |
RGD:6480464 |
CTD |
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions |
EXP |
19 |
54,738,556 |
54,750,349 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
increases phosphorylation |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Angptl4 |
angiopoietin-like 4 |
|
affects abundance |
ISO |
7 |
16,261,623 |
16,267,852 |
RGD:6480464 |
CTD |
| G |
Apoa1 |
apolipoprotein A-I |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Aqp9 |
aquaporin 9 |
|
increases abundance |
ISO |
8 |
75,611,485 |
75,651,646 |
RGD:6480464 |
CTD |
| G |
Aqp9 |
aquaporin 9 |
|
multiple interactions |
ISO |
8 |
75,611,485 |
75,651,646 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
multiple interactions |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Gk |
glycerol kinase |
|
multiple interactions |
EXP |
X |
72,416,872 |
72,493,296 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
increases expression |
ISO |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Mgll |
monoglyceride lipase |
|
increases chemical synthesis |
EXP |
4 |
122,822,493 |
122,922,892 |
RGD:6480464 |
CTD |
| G |
Mgll |
monoglyceride lipase |
|
multiple interactions |
EXP |
4 |
122,822,493 |
122,922,892 |
RGD:6480464 |
CTD |
| G |
Mt1a |
metallothionein 1a |
|
increases expression |
ISO |
19 |
11,261,631 |
11,262,647 |
RGD:6480464 |
CTD |
| G |
Mt2A |
metallothionein 2A |
|
increases expression |
ISO |
19 |
11,267,811 |
11,268,585 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
decreases expression |
ISO |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Nppa |
natriuretic peptide A |
|
increases expression |
ISO |
5 |
165,074,518 |
165,075,827 |
RGD:6480464 |
CTD |
| G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
|
multiple interactions |
ISO |
7 |
140,012,807 |
140,020,590 |
RGD:6480464 |
CTD |
| G |
Oat |
ornithine aminotransferase |
|
multiple interactions |
EXP |
1 |
192,026,623 |
192,046,404 |
RGD:6480464 |
CTD |
| G |
Pklr |
pyruvate kinase, liver and RBC |
|
increases expression |
EXP |
2 |
181,214,853 |
181,223,505 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
increases secretion |
ISO |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
EXP |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
decreases expression |
EXP |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Si |
sucrase-isomaltase (alpha-glucosidase) |
|
increases expression |
EXP |
2 |
163,520,975 |
163,601,280 |
RGD:6480464 |
CTD |
| G |
Slc2a2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
|
increases expression |
EXP |
2 |
116,036,501 |
116,065,834 |
RGD:6480464 |
CTD |
| G |
Slc5a1 |
solute carrier family 5 (sodium/glucose cotransporter), member 1 |
|
increases expression |
EXP |
14 |
83,311,232 |
83,370,657 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases activity |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
glycerol 1-phosphate
|
| G |
Gk |
glycerol kinase |
|
multiple interactions |
EXP |
X |
72,416,872 |
72,493,296 |
RGD:6480464 |
CTD |
glycerol 2-phosphate
|
| G |
Alpl |
alkaline phosphatase, liver/bone/kidney |
|
increases hydrolysis |
ISO |
5 |
156,501,739 |
156,558,727 |
RGD:6480464 |
CTD |
| G |
Alpl |
alkaline phosphatase, liver/bone/kidney |
|
multiple interactions |
ISO |
5 |
156,501,739 |
156,558,727 |
RGD:6480464 |
CTD |
| G |
Alpl |
alkaline phosphatase, liver/bone/kidney |
|
increases activity |
ISO |
5 |
156,501,739 |
156,558,727 |
RGD:6480464 |
CTD |
| G |
Alpl |
alkaline phosphatase, liver/bone/kidney |
|
increases degradation |
ISO |
5 |
156,501,739 |
156,558,727 |
RGD:6480464 |
CTD |
| G |
Alpl |
alkaline phosphatase, liver/bone/kidney |
|
increases expression |
ISO |
5 |
156,501,739 |
156,558,727 |
RGD:6480464 |
CTD |
| G |
Alpl |
alkaline phosphatase, liver/bone/kidney |
|
multiple interactions |
ISO |
5 |
156,501,739 |
156,558,727 |
RGD:6480464 |
CTD |
| G |
Bglap |
bone gamma-carboxyglutamate (gla) protein |
|
multiple interactions |
ISO |
2 |
180,482,313 |
180,483,290 |
RGD:6480464 |
CTD |
| G |
Bmp1 |
bone morphogenetic protein 1 |
|
multiple interactions |
EXP |
15 |
50,878,144 |
50,922,313 |
RGD:6480464 |
CTD |
| G |
Bmp2 |
bone morphogenetic protein 2 |
|
multiple interactions |
EXP |
3 |
121,372,692 |
121,381,236 |
RGD:6480464 |
CTD |
| G |
Bmp3 |
bone morphogenetic protein 3 |
|
multiple interactions |
EXP |
14 |
12,065,635 |
12,090,295 |
RGD:6480464 |
CTD |
| G |
Bmp7 |
bone morphogenetic protein 7 |
|
multiple interactions |
EXP |
3 |
163,723,429 |
163,799,567 |
RGD:6480464 |
CTD |
| G |
Cebpa |
CCAAT/enhancer binding protein (C/EBP), alpha |
|
multiple interactions |
ISO |
1 |
87,626,111 |
87,627,499 |
RGD:6480464 |
CTD |
| G |
Enpp1 |
ectonucleotide pyrophosphatase/phosphodiesterase 1 |
|
increases expression |
ISO |
1 |
21,223,678 |
21,287,411 |
RGD:6480464 |
CTD |
| G |
Enpp1 |
ectonucleotide pyrophosphatase/phosphodiesterase 1 |
|
increases activity |
ISO |
1 |
21,223,678 |
21,287,411 |
RGD:6480464 |
CTD |
| G |
Enpp1 |
ectonucleotide pyrophosphatase/phosphodiesterase 1 |
|
multiple interactions |
ISO |
1 |
21,223,678 |
21,287,411 |
RGD:6480464 |
CTD |
| G |
Fgf23 |
fibroblast growth factor 23 |
|
increases expression |
ISO |
4 |
163,468,604 |
163,476,325 |
RGD:6480464 |
CTD |
| G |
Gdf10 |
growth differentiation factor 10 |
|
multiple interactions |
EXP |
16 |
9,558,781 |
9,570,656 |
RGD:6480464 |
CTD |
| G |
Phex |
phosphate regulating endopeptidase homolog, X-linked |
|
increases expression |
ISO |
X |
58,911,144 |
59,168,857 |
RGD:6480464 |
CTD |
| G |
Phex |
phosphate regulating endopeptidase homolog, X-linked |
|
multiple interactions |
ISO |
X |
58,911,144 |
59,168,857 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Runx2 |
runt-related transcription factor 2 |
|
multiple interactions |
ISO |
9 |
11,869,234 |
12,025,219 |
RGD:6480464 |
CTD |
| G |
Scd1 |
stearoyl-Coenzyme A desaturase 1 |
|
multiple interactions |
ISO |
1 |
249,458,860 |
249,471,460 |
RGD:6480464 |
CTD |
| G |
Sparc |
secreted protein, acidic, cysteine-rich (osteonectin) |
|
multiple interactions |
ISO |
10 |
40,809,730 |
40,831,481 |
RGD:6480464 |
CTD |
| G |
Spp1 |
secreted phosphoprotein 1 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Src |
v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) |
|
multiple interactions |
ISO |
3 |
148,157,256 |
148,170,524 |
RGD:6480464 |
CTD |
| G |
Stc1 |
stanniocalcin 1 |
|
decreases expression |
EXP |
15 |
49,566,885 |
49,577,539 |
RGD:6480464 |
CTD |
| G |
Taz |
tafazzin |
|
multiple interactions |
ISO |
X |
160,319,389 |
160,326,974 |
RGD:6480464 |
CTD |
glycogen
|
| G |
Htr2b |
5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled |
|
multiple interactions |
ISO |
9 |
84,840,026 |
84,852,984 |
RGD:6480464 |
CTD |
| G |
Ins1 |
insulin 1 |
|
multiple interactions |
EXP |
1 |
258,001,134 |
258,001,688 |
RGD:6480464 |
CTD |
| G |
Ins1 |
insulin 1 |
|
increases abundance |
EXP |
1 |
258,001,134 |
258,001,688 |
RGD:6480464 |
CTD |
| G |
Ins1 |
insulin 1 |
|
increases chemical synthesis |
EXP |
1 |
258,001,134 |
258,001,688 |
RGD:6480464 |
CTD |
| G |
Ins2 |
insulin 2 |
|
multiple interactions |
ISO |
1 |
202,935,548 |
202,936,379 |
RGD:6480464 |
CTD |
| G |
Ins2 |
insulin 2 |
|
increases chemical synthesis |
ISO |
1 |
202,935,548 |
202,936,379 |
RGD:6480464 |
CTD |
| G |
Ins2 |
insulin 2 |
|
multiple interactions |
ISO |
1 |
202,935,548 |
202,936,379 |
RGD:6480464 |
CTD |
| G |
Ins2 |
insulin 2 |
|
increases chemical synthesis |
ISO |
1 |
202,935,548 |
202,936,379 |
RGD:6480464 |
CTD |
| G |
Ins2 |
insulin 2 |
|
increases chemical synthesis |
ISO |
1 |
202,935,548 |
202,936,379 |
RGD:6480464 |
CTD |
| G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
|
multiple interactions |
ISO |
3 |
58,366,693 |
58,394,116 |
RGD:6480464 |
CTD |
| G |
Src |
v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) |
|
multiple interactions |
ISO |
3 |
148,157,256 |
148,170,524 |
RGD:6480464 |
CTD |
heparan sulfate
|
| G |
Ccl5 |
chemokine (C-C motif) ligand 5 |
|
multiple interactions |
ISO |
10 |
71,605,791 |
71,610,330 |
RGD:6480464 |
CTD |
| G |
Cxcl1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
multiple interactions |
ISO |
14 |
18,690,339 |
18,692,118 |
RGD:6480464 |
CTD |
| G |
Cxcl10 |
chemokine (C-X-C motif) ligand 10 |
|
multiple interactions |
ISO |
14 |
17,265,986 |
17,268,183 |
RGD:6480464 |
CTD |
| G |
Fgf1 |
fibroblast growth factor 1 (acidic) |
|
affects binding |
ISO |
18 |
31,785,480 |
31,806,452 |
RGD:6480464 |
CTD |
| G |
Fgf10 |
fibroblast growth factor 10 |
|
affects activity |
ISO |
2 |
50,866,799 |
50,940,319 |
RGD:6480464 |
CTD |
| G |
Fgf10 |
fibroblast growth factor 10 |
|
affects activity |
ISO |
2 |
50,866,799 |
50,940,319 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
multiple interactions |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
increases activity |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
affects binding |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf4 |
fibroblast growth factor 4 |
|
affects binding |
ISO |
1 |
205,292,272 |
205,293,705 |
RGD:6480464 |
CTD |
| G |
Fgf7 |
fibroblast growth factor 7 |
|
affects binding |
ISO |
3 |
113,468,427 |
113,517,538 |
RGD:6480464 |
CTD |
| G |
Fgf8 |
fibroblast growth factor 8 |
|
affects binding |
ISO |
1 |
250,951,023 |
250,956,730 |
RGD:6480464 |
CTD |
| G |
Fgf8 |
fibroblast growth factor 8 |
|
increases activity |
ISO |
1 |
250,951,023 |
250,956,730 |
RGD:6480464 |
CTD |
| G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
|
affects binding |
ISO |
16 |
70,869,974 |
70,910,045 |
RGD:6480464 |
CTD |
| G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
|
increases activity |
ISO |
16 |
70,869,974 |
70,910,045 |
RGD:6480464 |
CTD |
| G |
Fgfr2 |
fibroblast growth factor receptor 2 |
|
decreases activity |
ISO |
1 |
189,482,975 |
189,589,279 |
RGD:6480464 |
CTD |
| G |
Fgfr3 |
fibroblast growth factor receptor 3 |
|
increases activity |
ISO |
14 |
82,683,191 |
82,697,229 |
RGD:6480464 |
CTD |
| G |
Fgfr4 |
fibroblast growth factor receptor 4 |
|
affects binding |
ISO |
17 |
15,512,144 |
15,527,348 |
RGD:6480464 |
CTD |
| G |
Gns |
glucosamine (N-acetyl)-6-sulfatase |
|
affects degradation |
ISO |
7 |
60,672,492 |
60,702,306 |
RGD:6480464 |
CTD |
| G |
Gpc1 |
glypican 1 |
|
affects binding |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Gpc1 |
glypican 1 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Hpse |
heparanase |
|
multiple interactions |
ISO |
14 |
10,144,322 |
10,185,115 |
RGD:6480464 |
CTD |
| G |
Hpse |
heparanase |
|
affects abundance |
ISO |
14 |
10,144,322 |
10,185,115 |
RGD:6480464 |
CTD |
| G |
Hpse |
heparanase |
|
decreases abundance |
EXP |
14 |
10,144,322 |
10,185,115 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Ndst1 |
N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1 |
|
multiple interactions |
ISO |
18 |
56,638,891 |
56,677,831 |
RGD:6480464 |
CTD |
| G |
Ndst2 |
N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 2 |
|
multiple interactions |
ISO |
15 |
3,788,239 |
3,798,682 |
RGD:6480464 |
CTD |
| G |
Prnp |
prion protein |
|
affects binding |
ISO |
3 |
119,676,137 |
119,691,507 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
multiple interactions |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
heparin
|
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
affects activity |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
multiple interactions |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
|
multiple interactions |
EXP |
11 |
25,434,262 |
25,443,144 |
RGD:6480464 |
CTD |
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions |
EXP |
19 |
54,738,556 |
54,750,349 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
EXP |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Apcs |
amyloid P component, serum |
|
increases expression |
ISO |
13 |
89,112,845 |
89,113,641 |
RGD:6480464 |
CTD |
| G |
Atp1b1 |
ATPase, Na+/K+ transporting, beta 1 polypeptide |
|
multiple interactions |
EXP |
13 |
80,214,056 |
80,234,576 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
increases expression |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
increases expression |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
increases expression |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
increases expression |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
increases expression |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
C3 |
complement component 3 |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
C3 |
complement component 3 |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
C5 |
complement component 5 |
|
decreases expression |
ISO |
3 |
14,011,115 |
14,102,744 |
RGD:6480464 |
CTD |
| G |
Cacna1e |
calcium channel, voltage-dependent, R type, alpha 1E subunit |
|
multiple interactions |
EXP |
13 |
69,367,254 |
69,683,943 |
RGD:6480464 |
CTD |
| G |
Casp12 |
caspase 12 |
|
multiple interactions |
ISO |
8 |
2,082,933 |
2,110,511 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
decreases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
increases activity |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Ccl11 |
chemokine (C-C motif) ligand 11 |
|
affects binding |
ISO |
10 |
70,279,161 |
70,283,762 |
RGD:6480464 |
CTD |
| G |
Ccl11 |
chemokine (C-C motif) ligand 11 |
|
multiple interactions |
ISO |
10 |
70,279,161 |
70,283,762 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
decreases expression |
EXP |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Cd40lg |
CD40 ligand |
|
decreases expression |
ISO |
X |
141,925,019 |
141,937,183 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
EXP |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
decreases expression |
ISO |
4 |
171,841,705 |
171,846,506 |
RGD:6480464 |
CTD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
increases expression |
ISO |
4 |
171,841,705 |
171,846,506 |
RGD:6480464 |
CTD |
| G |
Col18a1 |
collagen, type XVIII, alpha 1 |
|
affects binding |
ISO |
20 |
11,920,816 |
11,982,468 |
RGD:6480464 |
CTD |
| G |
Crp |
C-reactive protein, pentraxin-related |
|
increases expression |
ISO |
13 |
88,702,243 |
88,703,153 |
RGD:6480464 |
CTD |
| G |
Csf3 |
colony stimulating factor 3 (granulocyte) |
|
multiple interactions |
EXP |
10 |
87,473,990 |
87,476,365 |
RGD:6480464 |
CTD |
| G |
Cxcl12 |
chemokine (C-X-C motif) ligand 12 |
|
decreases expression |
ISO |
4 |
153,503,576 |
153,516,423 |
RGD:6480464 |
CTD |
| G |
Cxcl2 |
chemokine (C-X-C motif) ligand 2 |
|
multiple interactions |
EXP |
14 |
18,677,129 |
18,679,175 |
RGD:6480464 |
CTD |
| G |
Cxcr4 |
chemokine (C-X-C motif) receptor 4 |
|
decreases expression |
ISO |
13 |
41,308,286 |
41,312,190 |
RGD:6480464 |
CTD |
| G |
Cxcr7 |
chemokine (C-X-C motif) receptor 7 |
|
multiple interactions |
EXP |
9 |
89,343,528 |
89,355,053 |
RGD:6480464 |
CTD |
| G |
Des |
desmin |
|
decreases expression |
EXP |
9 |
74,637,783 |
74,645,499 |
RGD:6480464 |
CTD |
| G |
E2f1 |
E2F transcription factor 1 |
|
decreases expression |
ISO |
3 |
145,032,489 |
145,043,729 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
multiple interactions |
ISO |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
decreases expression |
ISO |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
multiple interactions |
ISO |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
decreases secretion |
ISO |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
multiple interactions |
EXP |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
multiple interactions |
ISO |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
decreases expression |
ISO |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
decreases secretion |
ISO |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
decreases activity |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
decreases expression |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
increases phosphorylation |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egln3 |
EGL nine homolog 3 (C. elegans) |
|
multiple interactions |
EXP |
6 |
74,451,038 |
74,476,506 |
RGD:6480464 |
CTD |
| G |
F10 |
coagulation factor X |
|
decreases activity |
ISO |
16 |
81,327,237 |
81,346,544 |
RGD:6480464 |
CTD |
| G |
F10 |
coagulation factor X |
|
decreases activity |
EXP |
16 |
81,327,237 |
81,346,544 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
multiple interactions |
ISO |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
multiple interactions |
ISO |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
increases expression |
ISO |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
multiple interactions |
ISO |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
multiple interactions |
ISO |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
multiple interactions |
ISO |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
multiple interactions |
ISO |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
decreases expression |
ISO |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
increases expression |
ISO |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
multiple interactions |
ISO |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
multiple interactions |
ISO |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
F2r |
coagulation factor II (thrombin) receptor |
|
multiple interactions |
ISO |
2 |
25,985,800 |
25,989,072 |
RGD:6480464 |
CTD |
| G |
Fas |
Fas (TNF receptor superfamily, member 6) |
|
increases expression |
ISO |
1 |
238,259,443 |
238,274,745 |
RGD:6480464 |
CTD |
| G |
Fcgr2a |
Fc fragment of IgG, low affinity IIa, receptor |
|
affects binding |
ISO |
13 |
86,898,651 |
86,911,743 |
RGD:6480464 |
CTD |
| G |
Fga |
fibrinogen alpha chain |
|
increases cleavage |
ISO |
2 |
174,737,640 |
174,753,598 |
RGD:6480464 |
CTD |
| G |
Fgf1 |
fibroblast growth factor 1 (acidic) |
|
multiple interactions |
ISO |
18 |
31,785,480 |
31,806,452 |
RGD:6480464 |
CTD |
| G |
Fgf1 |
fibroblast growth factor 1 (acidic) |
|
multiple interactions |
ISO |
18 |
31,785,480 |
31,806,452 |
RGD:6480464 |
CTD |
| G |
Fgf1 |
fibroblast growth factor 1 (acidic) |
|
multiple interactions |
EXP |
18 |
31,785,480 |
31,806,452 |
RGD:6480464 |
CTD |
| G |
Fgf1 |
fibroblast growth factor 1 (acidic) |
|
affects binding |
EXP |
18 |
31,785,480 |
31,806,452 |
RGD:6480464 |
CTD |
| G |
Fgf1 |
fibroblast growth factor 1 (acidic) |
|
multiple interactions |
EXP |
18 |
31,785,480 |
31,806,452 |
RGD:6480464 |
CTD |
| G |
Fgf1 |
fibroblast growth factor 1 (acidic) |
|
multiple interactions |
EXP |
18 |
31,785,480 |
31,806,452 |
RGD:6480464 |
CTD |
| G |
Fgf10 |
fibroblast growth factor 10 |
|
multiple interactions |
ISO |
2 |
50,866,799 |
50,940,319 |
RGD:6480464 |
CTD |
| G |
Fgf19 |
fibroblast growth factor 19 |
|
affects binding |
ISO |
1 |
205,324,890 |
205,328,178 |
RGD:6480464 |
CTD |
| G |
Fgf19 |
fibroblast growth factor 19 |
|
multiple interactions |
ISO |
1 |
205,324,890 |
205,328,178 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
affects binding |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
affects binding |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
multiple interactions |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
multiple interactions |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
affects activity |
EXP |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
multiple interactions |
EXP |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
affects binding |
EXP |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
multiple interactions |
EXP |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
decreases expression |
EXP |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf23 |
fibroblast growth factor 23 |
|
increases activity |
ISO |
4 |
163,468,604 |
163,476,325 |
RGD:6480464 |
CTD |
| G |
Fgf3 |
fibroblast growth factor 3 |
|
affects activity |
ISO |
1 |
205,269,480 |
205,273,404 |
RGD:6480464 |
CTD |
| G |
Fgf4 |
fibroblast growth factor 4 |
|
multiple interactions |
ISO |
1 |
205,292,272 |
205,293,705 |
RGD:6480464 |
CTD |
| G |
Fgf5 |
fibroblast growth factor 5 |
|
affects activity |
ISO |
14 |
12,713,971 |
12,734,634 |
RGD:6480464 |
CTD |
| G |
Fgf7 |
fibroblast growth factor 7 |
|
affects binding |
EXP |
3 |
113,468,427 |
113,517,538 |
RGD:6480464 |
CTD |
| G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
|
affects binding |
ISO |
16 |
70,869,974 |
70,910,045 |
RGD:6480464 |
CTD |
| G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
|
multiple interactions |
ISO |
16 |
70,869,974 |
70,910,045 |
RGD:6480464 |
CTD |
| G |
Fgfr2 |
fibroblast growth factor receptor 2 |
|
multiple interactions |
ISO |
1 |
189,482,975 |
189,589,279 |
RGD:6480464 |
CTD |
| G |
Fgfr2 |
fibroblast growth factor receptor 2 |
|
multiple interactions |
ISO |
1 |
189,482,975 |
189,589,279 |
RGD:6480464 |
CTD |
| G |
Fgfr2 |
fibroblast growth factor receptor 2 |
|
affects activity |
ISO |
1 |
189,482,975 |
189,589,279 |
RGD:6480464 |
CTD |
| G |
Fgfr2 |
fibroblast growth factor receptor 2 |
|
multiple interactions |
ISO |
1 |
189,482,975 |
189,589,279 |
RGD:6480464 |
CTD |
| G |
Fgfr2 |
fibroblast growth factor receptor 2 |
|
affects binding |
EXP |
1 |
189,482,975 |
189,589,279 |
RGD:6480464 |
CTD |
| G |
Fgfr3 |
fibroblast growth factor receptor 3 |
|
affects activity |
ISO |
14 |
82,683,191 |
82,697,229 |
RGD:6480464 |
CTD |
| G |
Fgfr3 |
fibroblast growth factor receptor 3 |
|
multiple interactions |
ISO |
14 |
82,683,191 |
82,697,229 |
RGD:6480464 |
CTD |
| G |
Fgfr4 |
fibroblast growth factor receptor 4 |
|
affects binding |
ISO |
17 |
15,512,144 |
15,527,348 |
RGD:6480464 |
CTD |
| G |
Fgfr4 |
fibroblast growth factor receptor 4 |
|
multiple interactions |
ISO |
17 |
15,512,144 |
15,527,348 |
RGD:6480464 |
CTD |
| G |
Fgfr4 |
fibroblast growth factor receptor 4 |
|
multiple interactions |
EXP |
17 |
15,512,144 |
15,527,348 |
RGD:6480464 |
CTD |
| G |
Fgfr4 |
fibroblast growth factor receptor 4 |
|
multiple interactions |
ISO |
17 |
15,512,144 |
15,527,348 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
decreases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Gata4 |
GATA binding protein 4 |
|
multiple interactions |
EXP |
15 |
42,472,793 |
42,519,569 |
RGD:6480464 |
CTD |
| G |
Gns |
glucosamine (N-acetyl)-6-sulfatase |
|
affects degradation |
ISO |
7 |
60,672,492 |
60,702,306 |
RGD:6480464 |
CTD |
| G |
Gzmb |
granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) |
|
multiple interactions |
EXP |
15 |
35,195,075 |
35,198,506 |
RGD:6480464 |
CTD |
| G |
Gzmbl2 |
Granzyme B-like 2 |
|
multiple interactions |
EXP |
15 |
35,061,676 |
35,074,048 |
RGD:6480464 |
CTD |
| G |
Hgf |
hepatocyte growth factor |
|
multiple interactions |
ISO |
4 |
14,864,357 |
14,932,513 |
RGD:6480464 |
CTD |
| G |
Hgf |
hepatocyte growth factor |
|
increases expression |
ISO |
4 |
14,864,357 |
14,932,513 |
RGD:6480464 |
CTD |
| G |
Hgf |
hepatocyte growth factor |
|
affects binding |
ISO |
4 |
14,864,357 |
14,932,513 |
RGD:6480464 |
CTD |
| G |
Hpse |
heparanase |
|
multiple interactions |
ISO |
14 |
10,144,322 |
10,185,115 |
RGD:6480464 |
CTD |
| G |
Hrg |
histidine-rich glycoprotein |
|
multiple interactions |
ISO |
11 |
80,248,578 |
80,264,179 |
RGD:6480464 |
CTD |
| G |
Igsf10 |
immunoglobulin superfamily, member 10 |
|
multiple interactions |
EXP |
2 |
148,704,646 |
148,734,103 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Itgam |
integrin, alpha M |
|
decreases expression |
ISO |
1 |
187,334,413 |
187,385,583 |
RGD:6480464 |
CTD |
| G |
Itgam |
integrin, alpha M |
|
increases expression |
ISO |
1 |
187,334,413 |
187,385,583 |
RGD:6480464 |
CTD |
| G |
Itgax |
integrin, alpha X |
|
decreases expression |
ISO |
1 |
187,396,184 |
187,416,273 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
multiple interactions |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
multiple interactions |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Klf4 |
Kruppel-like factor 4 (gut) |
|
multiple interactions |
EXP |
5 |
73,446,928 |
73,451,286 |
RGD:6480464 |
CTD |
| G |
Krt18 |
keratin 18 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Lpl |
lipoprotein lipase |
|
multiple interactions |
EXP |
16 |
22,533,105 |
22,556,905 |
RGD:6480464 |
CTD |
| G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
|
multiple interactions |
EXP |
8 |
68,379,074 |
68,451,554 |
RGD:6480464 |
CTD |
| G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
|
multiple interactions |
EXP |
7 |
10,074,654 |
10,094,003 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases activity |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases activity |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapt |
microtubule-associated protein tau |
|
multiple interactions |
ISO |
10 |
93,411,098 |
93,508,762 |
RGD:6480464 |
CTD |
| G |
Mmp1 |
matrix metallopeptidase 1 (interstitial collagenase) |
|
decreases activity |
ISO |
8 |
4,333,773 |
4,354,284 |
RGD:6480464 |
CTD |
| G |
Mmp2 |
matrix metallopeptidase 2 |
|
decreases activity |
ISO |
19 |
15,246,036 |
15,275,061 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
decreases activity |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
increases expression |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
increases expression |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
multiple interactions |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
increases expression |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
increases expression |
ISO |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
decreases expression |
EXP |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
increases expression |
ISO |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Nfatc3 |
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 |
|
multiple interactions |
EXP |
19 |
35,907,800 |
35,982,095 |
RGD:6480464 |
CTD |
| G |
Pdgfb |
platelet-derived growth factor beta polypeptide |
|
affects expression |
EXP |
7 |
118,244,385 |
118,262,021 |
RGD:6480464 |
CTD |
| G |
Pf4 |
platelet factor 4 |
|
affects binding |
ISO |
14 |
18,812,550 |
18,813,259 |
RGD:6480464 |
CTD |
| G |
Pf4 |
platelet factor 4 |
|
affects binding |
ISO |
14 |
18,812,550 |
18,813,259 |
RGD:6480464 |
CTD |
| G |
Pf4 |
platelet factor 4 |
|
increases secretion |
ISO |
14 |
18,812,550 |
18,813,259 |
RGD:6480464 |
CTD |
| G |
Pf4 |
platelet factor 4 |
|
increases secretion |
ISO |
14 |
18,812,550 |
18,813,259 |
RGD:6480464 |
CTD |
| G |
Pf4 |
platelet factor 4 |
|
affects binding |
ISO |
14 |
18,812,550 |
18,813,259 |
RGD:6480464 |
CTD |
| G |
Plat |
plasminogen activator, tissue |
|
increases expression |
ISO |
16 |
73,711,323 |
73,736,328 |
RGD:6480464 |
CTD |
| G |
Plat |
plasminogen activator, tissue |
|
increases expression |
ISO |
16 |
73,711,323 |
73,736,328 |
RGD:6480464 |
CTD |
| G |
Plg |
plasminogen |
|
multiple interactions |
ISO |
1 |
42,782,464 |
42,825,149 |
RGD:6480464 |
CTD |
| G |
Potef |
POTE ankyrin domain family, member F |
|
multiple interactions |
EXP |
18 |
24,420,779 |
24,422,284 |
RGD:6480464 |
CTD |
| G |
Ppbp |
pro-platelet basic protein (chemokine (C-X-C motif) ligand 7) |
|
increases secretion |
ISO |
14 |
18,816,434 |
18,817,238 |
RGD:6480464 |
CTD |
| G |
Proc |
protein C |
|
increases activity |
ISO |
18 |
24,563,368 |
24,573,715 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptk2 |
protein tyrosine kinase 2 |
|
decreases phosphorylation |
ISO |
7 |
110,933,298 |
111,084,554 |
RGD:6480464 |
CTD |
| G |
Pxn |
paxillin |
|
decreases phosphorylation |
ISO |
12 |
42,322,193 |
42,370,507 |
RGD:6480464 |
CTD |
| G |
Rac1 |
ras-related C3 botulinum toxin substrate 1 |
|
multiple interactions |
EXP |
12 |
11,380,314 |
11,400,531 |
RGD:6480464 |
CTD |
| G |
Rb1 |
retinoblastoma 1 |
|
multiple interactions |
ISO |
15 |
53,828,881 |
53,962,099 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
S100a1 |
S100 calcium binding protein A1 |
|
affects expression |
EXP |
2 |
182,784,818 |
182,787,370 |
RGD:6480464 |
CTD |
| G |
S100a6 |
S100 calcium binding protein A6 |
|
affects expression |
EXP |
2 |
182,895,080 |
182,896,305 |
RGD:6480464 |
CTD |
| G |
S100b |
S100 calcium binding protein B |
|
affects expression |
EXP |
20 |
12,791,440 |
12,824,508 |
RGD:6480464 |
CTD |
| G |
Sell |
selectin L |
|
decreases expression |
ISO |
13 |
79,827,342 |
79,845,296 |
RGD:6480464 |
CTD |
| G |
Sell |
selectin L |
|
increases expression |
ISO |
13 |
79,827,342 |
79,845,296 |
RGD:6480464 |
CTD |
| G |
Selp |
selectin P |
|
multiple interactions |
ISO |
13 |
79,886,614 |
79,922,180 |
RGD:6480464 |
CTD |
| G |
Selp |
selectin P |
|
increases expression |
ISO |
13 |
79,886,614 |
79,922,180 |
RGD:6480464 |
CTD |
| G |
Serpinc1 |
serpin peptidase inhibitor, clade C (antithrombin), member 1 |
|
decreases expression |
ISO |
13 |
76,548,456 |
76,562,724 |
RGD:6480464 |
CTD |
| G |
Serpinc1 |
serpin peptidase inhibitor, clade C (antithrombin), member 1 |
|
multiple interactions |
ISO |
13 |
76,548,456 |
76,562,724 |
RGD:6480464 |
CTD |
| G |
Serpinc1 |
serpin peptidase inhibitor, clade C (antithrombin), member 1 |
|
decreases expression |
ISO |
13 |
76,548,456 |
76,562,724 |
RGD:6480464 |
CTD |
| G |
Serpinc1 |
serpin peptidase inhibitor, clade C (antithrombin), member 1 |
|
multiple interactions |
ISO |
13 |
76,548,456 |
76,562,724 |
RGD:6480464 |
CTD |
| G |
Serpine1 |
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 |
|
multiple interactions |
EXP |
12 |
20,931,996 |
20,942,374 |
RGD:6480464 |
CTD |
| G |
Slc5a3 |
solute carrier family 5 (sodium/myo-inositol cotransporter), member 3 |
|
multiple interactions |
EXP |
11 |
32,063,275 |
32,065,721 |
RGD:6480464 |
CTD |
| G |
Slk |
STE20-like kinase |
|
multiple interactions |
EXP |
1 |
252,954,514 |
253,007,330 |
RGD:6480464 |
CTD |
| G |
Tfrc |
transferrin receptor |
|
multiple interactions |
EXP |
11 |
69,976,258 |
69,998,098 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
decreases expression |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
decreases expression |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
affects binding |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
inulin
|
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Fas |
Fas (TNF receptor superfamily, member 6) |
|
increases expression |
ISO |
1 |
238,259,443 |
238,274,745 |
RGD:6480464 |
CTD |
| G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
|
multiple interactions |
ISO |
8 |
48,379,075 |
48,385,553 |
RGD:6480464 |
CTD |
| G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
|
increases transport |
ISO |
8 |
48,379,075 |
48,385,553 |
RGD:6480464 |
CTD |
| G |
Prkcb |
protein kinase C, beta |
|
multiple interactions |
ISO |
1 |
181,117,512 |
181,459,856 |
RGD:6480464 |
CTD |
| G |
Prkce |
protein kinase C, epsilon |
|
multiple interactions |
ISO |
6 |
9,631,234 |
10,097,311 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
iopromide
|
| G |
Edn1 |
endothelin 1 |
|
increases expression |
EXP |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
decreases expression |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
isosorbide dinitrate
|
| G |
Edn1 |
endothelin 1 |
|
multiple interactions |
ISO |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
G6pd |
glucose-6-phosphate dehydrogenase |
|
decreases response to substance |
ISO |
X |
160,186,450 |
160,192,316 |
RGD:6480464 |
CTD |
| G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
|
multiple interactions |
ISO |
4 |
6,158,847 |
6,179,441 |
RGD:6480464 |
CTD |
isosorbide mononitrate
|
| G |
Pafah1b1 |
platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 |
|
multiple interactions |
EXP |
10 |
61,955,348 |
62,037,871 |
RGD:6480464 |
CTD |
nitroglycerin
|
| G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
|
increases expression |
EXP |
8 |
57,044,478 |
57,072,970 |
RGD:6480464 |
CTD |
| G |
Actb |
actin, beta |
|
decreases expression |
EXP |
12 |
12,047,070 |
12,050,040 |
RGD:6480464 |
CTD |
| G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
|
decreases expression |
EXP |
1 |
223,731,675 |
223,773,285 |
RGD:6480464 |
CTD |
| G |
Aldh2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
multiple interactions |
ISO |
12 |
36,081,778 |
36,116,445 |
RGD:6480464 |
CTD |
| G |
Aldh2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
affects response to substance |
ISO |
12 |
36,081,778 |
36,116,445 |
RGD:6480464 |
CTD |
| G |
Aldh2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
affects metabolic processing |
ISO |
12 |
36,081,778 |
36,116,445 |
RGD:6480464 |
CTD |
| G |
Aldh2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
multiple interactions |
ISO |
12 |
36,081,778 |
36,116,445 |
RGD:6480464 |
CTD |
| G |
Aldh2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
affects response to substance |
ISO |
12 |
36,081,778 |
36,116,445 |
RGD:6480464 |
CTD |
| G |
Aldh2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
affects response to substance |
ISO |
12 |
36,081,778 |
36,116,445 |
RGD:6480464 |
CTD |
| G |
Aldh2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
decreases activity |
ISO |
12 |
36,081,778 |
36,116,445 |
RGD:6480464 |
CTD |
| G |
Aldh2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
decreases activity |
ISO |
12 |
36,081,778 |
36,116,445 |
RGD:6480464 |
CTD |
| G |
Aldh2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
multiple interactions |
EXP |
12 |
36,081,778 |
36,116,445 |
RGD:6480464 |
CTD |
| G |
Aldh2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
multiple interactions |
EXP |
12 |
36,081,778 |
36,116,445 |
RGD:6480464 |
CTD |
| G |
Aldh2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
multiple interactions |
EXP |
12 |
36,081,778 |
36,116,445 |
RGD:6480464 |
CTD |
| G |
Aldh2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
decreases activity |
EXP |
12 |
36,081,778 |
36,116,445 |
RGD:6480464 |
CTD |
| G |
Aldh2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
decreases expression |
EXP |
12 |
36,081,778 |
36,116,445 |
RGD:6480464 |
CTD |
| G |
Aldh2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
decreases expression |
EXP |
12 |
36,081,778 |
36,116,445 |
RGD:6480464 |
CTD |
| G |
Aldh2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
decreases activity |
EXP |
12 |
36,081,778 |
36,116,445 |
RGD:6480464 |
CTD |
| G |
Aldh2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
decreases activity |
EXP |
12 |
36,081,778 |
36,116,445 |
RGD:6480464 |
CTD |
| G |
Aldh2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
decreases expression |
EXP |
12 |
36,081,778 |
36,116,445 |
RGD:6480464 |
CTD |
| G |
Aldh2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
decreases activity |
EXP |
12 |
36,081,778 |
36,116,445 |
RGD:6480464 |
CTD |
| G |
Aldh2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
increases response to substance |
ISO |
12 |
36,081,778 |
36,116,445 |
RGD:6480464 |
CTD |
| G |
Aldh2 |
aldehyde dehydrogenase 2 family (mitochondrial) |
|
decreases activity |
ISO |
12 |
36,081,778 |
36,116,445 |
RGD:6480464 |
CTD |
| G |
Alox15 |
arachidonate 15-lipoxygenase |
|
decreases expression |
EXP |
10 |
57,185,939 |
57,194,388 |
RGD:6480464 |
CTD |
| G |
Ap2m1 |
adaptor-related protein complex 2, mu 1 subunit |
|
increases expression |
EXP |
11 |
82,585,474 |
82,591,832 |
RGD:6480464 |
CTD |
| G |
Apex1 |
APEX nuclease (multifunctional DNA repair enzyme) 1 |
|
increases expression |
EXP |
15 |
26,904,124 |
26,906,224 |
RGD:6480464 |
CTD |
| G |
Apoa1 |
apolipoprotein A-I |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Arl2 |
ADP-ribosylation factor-like 2 |
|
increases expression |
EXP |
1 |
208,909,458 |
208,921,401 |
RGD:6480464 |
CTD |
| G |
Atp5a1 |
ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle |
|
decreases expression |
EXP |
18 |
74,735,267 |
74,743,088 |
RGD:6480464 |
CTD |
| G |
B2m |
beta-2 microglobulin |
|
affects expression |
ISO |
3 |
108,927,919 |
108,932,718 |
RGD:6480464 |
CTD |
| G |
Bckdhb |
branched chain keto acid dehydrogenase E1, beta polypeptide |
|
decreases expression |
EXP |
8 |
88,997,979 |
89,191,017 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
C3 |
complement component 3 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Calca |
calcitonin-related polypeptide alpha |
|
multiple interactions |
EXP |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Calca |
calcitonin-related polypeptide alpha |
|
affects expression |
ISO |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Calca |
calcitonin-related polypeptide alpha |
|
multiple interactions |
EXP |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Calca |
calcitonin-related polypeptide alpha |
|
multiple interactions |
EXP |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Calca |
calcitonin-related polypeptide alpha |
|
increases expression |
EXP |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Calca |
calcitonin-related polypeptide alpha |
|
increases expression |
EXP |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Calca |
calcitonin-related polypeptide alpha |
|
increases expression |
EXP |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Calm2 |
calmodulin 2 |
|
increases expression |
EXP |
6 |
64,161,641 |
64,162,751 |
RGD:6480464 |
CTD |
| G |
Capn2 |
calpain 2, (m/II) large subunit |
|
decreases expression |
EXP |
13 |
98,473,367 |
98,524,463 |
RGD:6480464 |
CTD |
| G |
Casp1 |
caspase 1 |
|
multiple interactions |
ISO |
8 |
2,027,976 |
2,036,872 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
decreases expression |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cd3d |
CD3 molecule, delta |
|
increases expression |
EXP |
8 |
47,932,151 |
47,936,744 |
RGD:6480464 |
CTD |
| G |
Cd5 |
Cd5 molecule |
|
decreases expression |
EXP |
1 |
213,213,327 |
213,234,277 |
RGD:6480464 |
CTD |
| G |
Cd53 |
Cd53 molecule |
|
decreases expression |
EXP |
2 |
202,186,125 |
202,234,570 |
RGD:6480464 |
CTD |
| G |
Cdc37 |
cell division cycle 37 |
|
increases expression |
EXP |
8 |
20,164,150 |
20,176,763 |
RGD:6480464 |
CTD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
increases expression |
EXP |
4 |
171,841,705 |
171,846,506 |
RGD:6480464 |
CTD |
| G |
Celf2 |
CUGBP, Elav-like family member 2 |
|
increases expression |
EXP |
17 |
82,708,354 |
83,025,139 |
RGD:6480464 |
CTD |
| G |
Ckb |
creatine kinase, brain |
|
decreases expression |
EXP |
6 |
136,452,215 |
136,455,122 |
RGD:6480464 |
CTD |
| G |
Clu |
clusterin |
|
decreases expression |
EXP |
15 |
45,365,779 |
45,405,314 |
RGD:6480464 |
CTD |
| G |
Cnr1 |
cannabinoid receptor 1 (brain) |
|
multiple interactions |
EXP |
5 |
50,427,173 |
50,445,471 |
RGD:6480464 |
CTD |
| G |
Cp |
ceruloplasmin (ferroxidase) |
|
decreases expression |
EXP |
2 |
105,086,278 |
105,135,367 |
RGD:6480464 |
CTD |
| G |
Crip2 |
cysteine-rich protein 2 |
|
decreases expression |
EXP |
6 |
138,147,462 |
138,152,407 |
RGD:6480464 |
CTD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
multiple interactions |
ISO |
8 |
125,978,161 |
125,987,670 |
RGD:6480464 |
CTD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
decreases localization |
ISO |
8 |
125,978,161 |
125,987,670 |
RGD:6480464 |
CTD |
| G |
Ctsd |
cathepsin D |
|
decreases expression |
EXP |
1 |
202,619,669 |
202,631,545 |
RGD:6480464 |
CTD |
| G |
Cybb |
cytochrome b-245, beta polypeptide |
|
multiple interactions |
ISO |
X |
25,514,572 |
25,547,181 |
RGD:6480464 |
CTD |
| G |
Cybb |
cytochrome b-245, beta polypeptide |
|
decreases response to substance |
ISO |
X |
25,514,572 |
25,547,181 |
RGD:6480464 |
CTD |
| G |
Cybb |
cytochrome b-245, beta polypeptide |
|
multiple interactions |
ISO |
X |
25,514,572 |
25,547,181 |
RGD:6480464 |
CTD |
| G |
Cybb |
cytochrome b-245, beta polypeptide |
|
increases expression |
ISO |
X |
25,514,572 |
25,547,181 |
RGD:6480464 |
CTD |
| G |
Cybb |
cytochrome b-245, beta polypeptide |
|
decreases expression |
EXP |
X |
25,514,572 |
25,547,181 |
RGD:6480464 |
CTD |
| G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
|
decreases expression |
EXP |
7 |
113,043,365 |
113,049,779 |
RGD:6480464 |
CTD |
| G |
Cyp2b15 |
cytochrome P450, family 2, subfamily b, polypeptide 15 |
|
decreases expression |
EXP |
1 |
81,839,930 |
81,852,366 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
increases expression |
EXP |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Dhcr7 |
7-dehydrocholesterol reductase |
|
decreases expression |
EXP |
1 |
204,245,562 |
204,258,913 |
RGD:6480464 |
CTD |
| G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
|
decreases expression |
EXP |
4 |
30,496,410 |
30,809,622 |
RGD:6480464 |
CTD |
| G |
Dyrk1a |
dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A |
|
decreases expression |
EXP |
11 |
34,879,733 |
34,970,998 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
decreases expression |
ISO |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
multiple interactions |
EXP |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
decreases expression |
EXP |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
increases expression |
EXP |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Elane |
elastase, neutrophil expressed |
|
increases expression |
ISO |
7 |
11,329,642 |
11,331,490 |
RGD:6480464 |
CTD |
| G |
Eln |
elastin |
|
increases expression |
EXP |
12 |
23,033,657 |
23,077,043 |
RGD:6480464 |
CTD |
| G |
Faah |
fatty acid amide hydrolase |
|
multiple interactions |
EXP |
5 |
136,310,965 |
136,329,817 |
RGD:6480464 |
CTD |
| G |
Faah |
fatty acid amide hydrolase |
|
increases activity |
EXP |
5 |
136,310,965 |
136,329,817 |
RGD:6480464 |
CTD |
| G |
Fas |
Fas (TNF receptor superfamily, member 6) |
|
multiple interactions |
ISO |
1 |
238,259,443 |
238,274,745 |
RGD:6480464 |
CTD |
| G |
Fgfr2 |
fibroblast growth factor receptor 2 |
|
increases expression |
EXP |
1 |
189,482,975 |
189,589,279 |
RGD:6480464 |
CTD |
| G |
Fmo1 |
flavin containing monooxygenase 1 |
|
decreases expression |
EXP |
13 |
78,503,770 |
78,536,359 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Gchfr |
GTP cyclohydrolase I feedback regulator |
|
decreases expression |
EXP |
3 |
105,683,288 |
105,687,349 |
RGD:6480464 |
CTD |
| G |
Gnb3 |
guanine nucleotide binding protein (G protein), beta polypeptide 3 |
|
affects response to substance |
ISO |
4 |
160,957,524 |
160,963,226 |
RGD:6480464 |
CTD |
| G |
Gng7 |
guanine nucleotide binding protein (G protein), gamma 7 |
|
decreases expression |
EXP |
7 |
10,203,112 |
10,271,719 |
RGD:6480464 |
CTD |
| G |
Grk6 |
G protein-coupled receptor kinase 6 |
|
decreases expression |
EXP |
17 |
15,220,992 |
15,236,617 |
RGD:6480464 |
CTD |
| G |
Grn |
granulin |
|
decreases expression |
EXP |
10 |
91,536,135 |
91,542,239 |
RGD:6480464 |
CTD |
| G |
Gsn |
gelsolin |
|
increases expression |
EXP |
3 |
14,360,245 |
14,386,313 |
RGD:6480464 |
CTD |
| G |
Gsta2 |
glutathione S-transferase alpha 2 |
|
decreases expression |
EXP |
8 |
83,299,249 |
83,312,958 |
RGD:6480464 |
CTD |
| G |
Gsta3 |
glutathione S-transferase alpha 3 |
|
affects metabolic processing |
EXP |
9 |
20,005,570 |
20,032,031 |
RGD:6480464 |
CTD |
| G |
Gstm2 |
glutathione S-transferase mu 2 |
|
affects metabolic processing |
EXP |
2 |
203,549,022 |
203,553,380 |
RGD:6480464 |
CTD |
| G |
Gtf3c1 |
general transcription factor IIIC, polypeptide 1, alpha |
|
increases expression |
EXP |
1 |
184,701,886 |
184,768,061 |
RGD:6480464 |
CTD |
| G |
Gucy1a3 |
guanylate cyclase 1, soluble, alpha 3 |
|
increases expression |
EXP |
2 |
173,756,824 |
173,818,316 |
RGD:6480464 |
CTD |
| G |
Gucy1b3 |
guanylate cyclase 1, soluble, beta 3 |
|
increases expression |
EXP |
2 |
173,683,153 |
173,735,298 |
RGD:6480464 |
CTD |
| G |
Gucy1b3 |
guanylate cyclase 1, soluble, beta 3 |
|
increases expression |
ISO |
2 |
173,683,153 |
173,735,298 |
RGD:6480464 |
CTD |
| G |
Gucy1b3 |
guanylate cyclase 1, soluble, beta 3 |
|
increases expression |
EXP |
2 |
173,683,153 |
173,735,298 |
RGD:6480464 |
CTD |
| G |
Gucy1b3 |
guanylate cyclase 1, soluble, beta 3 |
|
increases expression |
EXP |
2 |
173,683,153 |
173,735,298 |
RGD:6480464 |
CTD |
| G |
Hbb |
hemoglobin, beta |
|
increases expression |
EXP |
1 |
161,618,782 |
161,620,193 |
RGD:6480464 |
CTD |
| G |
Hdc |
histidine decarboxylase |
|
decreases expression |
EXP |
3 |
114,119,316 |
114,138,107 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
increases expression |
ISO |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
increases expression |
ISO |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
EXP |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
increases expression |
EXP |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Hpn |
hepsin |
|
increases expression |
EXP |
1 |
86,145,615 |
86,161,091 |
RGD:6480464 |
CTD |
| G |
Iapp |
islet amyloid polypeptide |
|
increases expression |
EXP |
4 |
179,855,956 |
179,860,871 |
RGD:6480464 |
CTD |
| G |
Id2 |
inhibitor of DNA binding 2 |
|
increases expression |
EXP |
6 |
42,781,476 |
42,783,307 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Irs3 |
insulin receptor substrate 3 |
|
increases expression |
EXP |
12 |
19,709,141 |
19,711,279 |
RGD:6480464 |
CTD |
| G |
Jtb |
jumping translocation breakpoint |
|
increases expression |
EXP |
2 |
182,471,061 |
182,476,268 |
RGD:6480464 |
CTD |
| G |
Kng2 |
kininogen 2 |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Maob |
monoamine oxidase B |
|
increases expression |
EXP |
X |
17,553,529 |
17,657,852 |
RGD:6480464 |
CTD |
| G |
Mecr |
mitochondrial trans-2-enoyl-CoA reductase |
|
decreases expression |
EXP |
5 |
150,700,130 |
150,725,219 |
RGD:6480464 |
CTD |
| G |
Mgll |
monoglyceride lipase |
|
multiple interactions |
EXP |
4 |
122,822,493 |
122,922,892 |
RGD:6480464 |
CTD |
| G |
Mgll |
monoglyceride lipase |
|
increases activity |
EXP |
4 |
122,822,493 |
122,922,892 |
RGD:6480464 |
CTD |
| G |
Mmp2 |
matrix metallopeptidase 2 |
|
increases expression |
ISO |
19 |
15,246,036 |
15,275,061 |
RGD:6480464 |
CTD |
| G |
Mmp7 |
matrix metallopeptidase 7 |
|
increases expression |
ISO |
8 |
4,526,018 |
4,533,730 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
increases activity |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
increases expression |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
decreases activity |
EXP |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Mxi1 |
MAX interactor 1, dimerization protein |
|
increases expression |
EXP |
1 |
259,219,584 |
259,259,979 |
RGD:6480464 |
CTD |
| G |
Myo9b |
myosin IXb |
|
decreases expression |
EXP |
16 |
18,434,261 |
18,519,220 |
RGD:6480464 |
CTD |
| G |
Ncam1 |
neural cell adhesion molecule 1 |
|
increases expression |
EXP |
8 |
52,822,350 |
53,120,572 |
RGD:6480464 |
CTD |
| G |
Ndufa5 |
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 5 |
|
decreases expression |
EXP |
4 |
50,649,500 |
50,657,858 |
RGD:6480464 |
CTD |
| G |
Nkx2-1 |
NK2 homeobox 1 |
|
decreases expression |
EXP |
6 |
76,916,943 |
76,920,133 |
RGD:6480464 |
CTD |
| G |
Nnat |
neuronatin |
|
increases expression |
EXP |
3 |
148,269,404 |
148,271,781 |
RGD:6480464 |
CTD |
| G |
Nos1 |
nitric oxide synthase 1, neuronal |
|
multiple interactions |
EXP |
12 |
39,812,500 |
39,869,484 |
RGD:6480464 |
CTD |
| G |
Nos1 |
nitric oxide synthase 1, neuronal |
|
multiple interactions |
EXP |
12 |
39,812,500 |
39,869,484 |
RGD:6480464 |
CTD |
| G |
Nos1 |
nitric oxide synthase 1, neuronal |
|
increases expression |
EXP |
12 |
39,812,500 |
39,869,484 |
RGD:6480464 |
CTD |
| G |
Nos1 |
nitric oxide synthase 1, neuronal |
|
increases expression |
EXP |
12 |
39,812,500 |
39,869,484 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
decreases expression |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
decreases expression |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
|
multiple interactions |
EXP |
4 |
6,158,847 |
6,179,441 |
RGD:6480464 |
CTD |
| G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
|
multiple interactions |
EXP |
4 |
6,158,847 |
6,179,441 |
RGD:6480464 |
CTD |
| G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
|
increases expression |
EXP |
4 |
6,158,847 |
6,179,441 |
RGD:6480464 |
CTD |
| G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
|
increases expression |
EXP |
4 |
6,158,847 |
6,179,441 |
RGD:6480464 |
CTD |
| G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
|
increases expression |
EXP |
4 |
6,158,847 |
6,179,441 |
RGD:6480464 |
CTD |
| G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
|
increases expression |
EXP |
4 |
6,158,847 |
6,179,441 |
RGD:6480464 |
CTD |
| G |
Nox1 |
NADPH oxidase 1 |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Nox4 |
NADPH oxidase 4 |
|
decreases expression |
EXP |
1 |
143,415,816 |
143,603,554 |
RGD:6480464 |
CTD |
| G |
Npy |
neuropeptide Y |
|
increases expression |
EXP |
4 |
78,038,013 |
78,045,187 |
RGD:6480464 |
CTD |
| G |
Paics |
phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase |
|
increases expression |
EXP |
14 |
33,492,707 |
33,509,389 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
decreases expression |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Pcsk1n |
proprotein convertase subtilisin/kexin type 1 inhibitor |
|
decreases expression |
EXP |
X |
26,614,585 |
26,618,027 |
RGD:6480464 |
CTD |
| G |
Pde1a |
phosphodiesterase 1A, calmodulin-dependent |
|
increases expression |
EXP |
3 |
62,650,092 |
62,928,487 |
RGD:6480464 |
CTD |
| G |
Pde1a |
phosphodiesterase 1A, calmodulin-dependent |
|
multiple interactions |
EXP |
3 |
62,650,092 |
62,928,487 |
RGD:6480464 |
CTD |
| G |
Pde2a |
phosphodiesterase 2A, cGMP-stimulated |
|
increases expression |
EXP |
1 |
158,921,607 |
159,013,829 |
RGD:6480464 |
CTD |
| G |
Pla2g1b |
phospholipase A2, group IB, pancreas |
|
increases expression |
EXP |
12 |
42,405,475 |
42,415,189 |
RGD:6480464 |
CTD |
| G |
Plaur |
plasminogen activator, urokinase receptor |
|
increases expression |
EXP |
1 |
79,708,646 |
79,712,881 |
RGD:6480464 |
CTD |
| G |
Pmp22 |
peripheral myelin protein 22 |
|
decreases expression |
EXP |
10 |
49,305,835 |
49,335,864 |
RGD:6480464 |
CTD |
| G |
Polr1b |
polymerase (RNA) I polypeptide B |
|
increases expression |
EXP |
3 |
116,706,483 |
116,730,946 |
RGD:6480464 |
CTD |
| G |
Ppp2cb |
protein phosphatase 2, catalytic subunit, beta isozyme |
|
decreases expression |
EXP |
16 |
62,330,513 |
62,351,968 |
RGD:6480464 |
CTD |
| G |
Prkg1 |
protein kinase, cGMP-dependent, type 1 |
|
decreases expression |
EXP |
1 |
234,420,597 |
235,765,375 |
RGD:6480464 |
CTD |
| G |
Ptgds |
prostaglandin D2 synthase (brain) |
|
increases expression |
EXP |
3 |
3,632,683 |
3,635,617 |
RGD:6480464 |
CTD |
| G |
Ptprr |
protein tyrosine phosphatase, receptor type, R |
|
increases expression |
EXP |
7 |
55,324,246 |
55,612,945 |
RGD:6480464 |
CTD |
| G |
Rab40c |
Rab40c, member RAS oncogene family |
|
increases expression |
EXP |
10 |
15,147,861 |
15,181,653 |
RGD:6480464 |
CTD |
| G |
Reg3b |
regenerating islet-derived 3 beta |
|
increases expression |
EXP |
4 |
112,355,773 |
112,359,011 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
increases localization |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
increases activity |
ISO |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Rgs8 |
regulator of G-protein signaling 8 |
|
increases expression |
EXP |
13 |
68,735,814 |
68,766,956 |
RGD:6480464 |
CTD |
| G |
Rheb |
Ras homolog enriched in brain |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Rps3a |
ribosomal protein S3a |
|
increases expression |
EXP |
2 |
178,092,351 |
178,096,720 |
RGD:6480464 |
CTD |
| G |
Scgb1a1 |
secretoglobin, family 1A, member 1 (uteroglobin) |
|
decreases expression |
EXP |
1 |
211,758,103 |
211,761,651 |
RGD:6480464 |
CTD |
| G |
Sdc4 |
syndecan 4 |
|
decreases expression |
EXP |
3 |
155,446,138 |
155,464,825 |
RGD:6480464 |
CTD |
| G |
Serpina3n |
serine (or cysteine) peptidase inhibitor, clade A, member 3N |
|
decreases expression |
EXP |
6 |
128,461,775 |
128,469,309 |
RGD:6480464 |
CTD |
| G |
Shank2 |
SH3 and multiple ankyrin repeat domains 2 |
|
increases expression |
EXP |
1 |
204,399,856 |
204,855,474 |
RGD:6480464 |
CTD |
| G |
Slc4a4 |
solute carrier family 4, sodium bicarbonate cotransporter, member 4 |
|
increases expression |
EXP |
14 |
20,381,545 |
20,739,216 |
RGD:6480464 |
CTD |
| G |
Snn |
stannin |
|
decreases expression |
EXP |
10 |
4,486,038 |
4,494,711 |
RGD:6480464 |
CTD |
| G |
Snrk |
SNF related kinase |
|
increases expression |
EXP |
8 |
121,958,351 |
121,968,989 |
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
EXP |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Stat3 |
signal transducer and activator of transcription 3 (acute-phase response factor) |
|
increases expression |
EXP |
10 |
89,821,078 |
89,872,970 |
RGD:6480464 |
CTD |
| G |
Syk |
spleen tyrosine kinase |
|
increases expression |
EXP |
17 |
18,440,672 |
18,498,001 |
RGD:6480464 |
CTD |
| G |
Syn2 |
synapsin II |
|
increases expression |
EXP |
4 |
151,255,241 |
151,413,220 |
RGD:6480464 |
CTD |
| G |
Tac1 |
tachykinin, precursor 1 |
|
affects expression |
EXP |
4 |
32,649,666 |
32,657,632 |
RGD:6480464 |
CTD |
| G |
Tcf4 |
transcription factor 4 |
|
multiple interactions |
ISO |
18 |
66,135,863 |
66,359,984 |
RGD:6480464 |
CTD |
| G |
Thy1 |
Thy-1 cell surface antigen |
|
decreases expression |
EXP |
8 |
47,027,721 |
47,031,857 |
RGD:6480464 |
CTD |
| G |
Tmpo |
thymopoietin |
|
increases expression |
EXP |
7 |
28,086,576 |
28,111,800 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnfrsf8 |
tumor necrosis factor receptor superfamily, member 8 |
|
decreases expression |
EXP |
5 |
163,716,462 |
163,762,235 |
RGD:6480464 |
CTD |
| G |
Umod |
uromodulin |
|
increases expression |
EXP |
1 |
177,729,212 |
177,742,552 |
RGD:6480464 |
CTD |
| G |
Uox |
urate oxidase |
|
decreases expression |
EXP |
2 |
244,795,552 |
244,832,143 |
RGD:6480464 |
CTD |
| G |
Vasp |
vasodilator-stimulated phosphoprotein |
|
multiple interactions |
ISO |
1 |
78,621,494 |
78,636,762 |
RGD:6480464 |
CTD |
| G |
Vasp |
vasodilator-stimulated phosphoprotein |
|
increases phosphorylation |
ISO |
1 |
78,621,494 |
78,636,762 |
RGD:6480464 |
CTD |
| G |
Vasp |
vasodilator-stimulated phosphoprotein |
|
multiple interactions |
EXP |
1 |
78,621,494 |
78,636,762 |
RGD:6480464 |
CTD |
| G |
Vasp |
vasodilator-stimulated phosphoprotein |
|
multiple interactions |
EXP |
1 |
78,621,494 |
78,636,762 |
RGD:6480464 |
CTD |
| G |
Vasp |
vasodilator-stimulated phosphoprotein |
|
decreases phosphorylation |
EXP |
1 |
78,621,494 |
78,636,762 |
RGD:6480464 |
CTD |
| G |
Vasp |
vasodilator-stimulated phosphoprotein |
|
increases phosphorylation |
EXP |
1 |
78,621,494 |
78,636,762 |
RGD:6480464 |
CTD |
| G |
Vasp |
vasodilator-stimulated phosphoprotein |
|
increases phosphorylation |
EXP |
1 |
78,621,494 |
78,636,762 |
RGD:6480464 |
CTD |
| G |
Vasp |
vasodilator-stimulated phosphoprotein |
|
decreases phosphorylation |
EXP |
1 |
78,621,494 |
78,636,762 |
RGD:6480464 |
CTD |
| G |
Vasp |
vasodilator-stimulated phosphoprotein |
|
increases phosphorylation |
ISO |
1 |
78,621,494 |
78,636,762 |
RGD:6480464 |
CTD |
| G |
Vtn |
vitronectin |
|
increases expression |
EXP |
10 |
64,609,242 |
64,612,322 |
RGD:6480464 |
CTD |
| G |
Ywhaz |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide |
|
decreases expression |
EXP |
7 |
72,283,825 |
72,306,126 |
RGD:6480464 |
CTD |
triolein
|
| G |
Abca1 |
ATP-binding cassette, subfamily A (ABC1), member 1 |
|
decreases expression |
ISO |
5 |
70,493,357 |
70,583,729 |
RGD:6480464 |
CTD |
| G |
Abcg5 |
ATP-binding cassette, subfamily G (WHITE), member 5 |
|
decreases expression |
ISO |
6 |
8,027,647 |
8,064,425 |
RGD:6480464 |
CTD |
| G |
Abcg8 |
ATP-binding cassette, subfamily G (WHITE), member 8 |
|
decreases expression |
ISO |
6 |
8,064,631 |
8,083,271 |
RGD:6480464 |
CTD |
| G |
Acaca |
acetyl-CoA carboxylase alpha |
|
multiple interactions |
ISO |
10 |
72,483,772 |
72,677,134 |
RGD:6480464 |
CTD |
| G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
|
decreases expression |
ISO |
9 |
74,039,204 |
74,068,648 |
RGD:6480464 |
CTD |
| G |
Fasn |
fatty acid synthase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
|
increases expression |
ISO |
2 |
27,127,504 |
27,149,580 |
RGD:6480464 |
CTD |
| G |
Mttp |
microsomal triglyceride transfer protein |
|
increases expression |
ISO |
2 |
235,613,710 |
235,654,848 |
RGD:6480464 |
CTD |
| G |
Npc1l1 |
NPC1-like 1 |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Scd1 |
stearoyl-Coenzyme A desaturase 1 |
|
multiple interactions |
ISO |
1 |
249,458,860 |
249,471,460 |
RGD:6480464 |
CTD |
| G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
|
multiple interactions |
ISO |
10 |
46,461,684 |
46,483,646 |
RGD:6480464 |
CTD |
xylitol
|
| G |
Oat |
ornithine aminotransferase |
|
multiple interactions |
EXP |
1 |
192,026,623 |
192,046,404 |
RGD:6480464 |
CTD |
Term paths to the root
|